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BSA Bovine serum albumin 
CHM Complete hybridoma medium 
Cmr Chioramphenicol 
CMP-NeuNAc CMP-N-acetylneuraminic acid 
CPS Capsular polysaccharide 
EDTA Disodium ethylenediaminetetraacetate 
ELISA Enzyme linked immuno-sorbent assay 
EtBr Ethidium bromide 
EtOH Ethanol 
FCA Freund's complete adjuvant 










HGPRT Hypoxanthine guanine phosphoribosyl transferase 
HS: Heat stable serotype or Penner serotype 
IFA Inimuno-fluorescent assay 
IMS Immunomagnetic separation 
IPTG Isopropyl 	-D-thiogalactopyranoside 




LT-PCR Long template polymerase chain reaction 
mAb Monoclonal antibody 
ManDAc N-acetylmannosamine 
MCM Myeloma culture media 
MFS Miller-Fisher syndrome 
MLEE Multi-locus enzyme electrophoresis 
Ix 
MLST Multi-locus sequence typing 
NCTC National Collection of Type Cultures 
Neu5Ac N-acetylneuramic acid 
NeuNAc N-acetylneuramic acid 
PAGE Polyacrylamide gel eletrophoresis 
PEG Polyethylene glycol 
PFGE Pulsed field gel electrophoresis 
RFLP Restriction fragment length polymorphism 
RPMI Roswell Park Memorial Institute 
SDS Sodium dodecyl sulphate 
SedHep Sedoheptulose-7-phosphate 
SFM Serum free medium 
ST Sequence type 
Tricine N-tris(hydroxymethyl)methylglycine 
TIGR The Institute for Genomic Research 
Tris Tris(hydroxymethyl)aminomethane 
UDP-GIcNAc UDP-N-acetyl-D-glucosamine 





Campylobacter jejuni is acknowledged as the most common cause of 
bacterial enteritis in the world. In addition its association with a number of 
autoimmune diseases makes reliable isolation and typing of major importance. 
PEB3, a cell envelope protein, was identified as a target for use in an 
immunomagnetic isolation system (IMS). Peb3 was cloned into Escherichia coil and 
expressed as a His-tagged construct (His.PEB3). Rabbits were then challenged with 
the purified construct to produce polyclonal antisera. Isolation of C. jejuni from a 
mixed culture (E. coil or Arcobacter spp. and C. jejuni) with polyclonal antisera was 
attempted but failed to capture whole C. jejuni cells. 
C. jejuni expresses two cell envelope associated polysaccharides: a short 
chain lipooligosaccharide (LOS) and a long chain lipid-linked polysaccharide, 
capsular polysaccharide (CPS). The Penner serotyping system has been shown to use 
CPS as its major discriminatory determinant. A novel molecular based typing system 
was devised based upon restriction fragment length polymorphism (RFLP) using the 
CPS locus as a discriminatory determinant. Primers for use in long template PCR 
(LT-PCR) were designed against the genes, kpsD, kpsS, gmhA2 and cj1430. The 
theoretical maximum amplicon length obtainable in LT-PCR is 40 kb; however, this 
is dependent on a number of factors including the %GC of the target amplicon. The 
low %GC of C. jejuni DNA prevented the amplification of the entire locus length 
(41 kb) in one reaction and by experimentation the maximum amplifiable length 
was determined to be 25 kb. This maximum length was only achieved sporadically 
and the maximum length that could be reliably amplified was 15 kb. Because of 
this limitation only the amplicon kpsS-grnhA2 was used in the typing scheme. 
41 
Amplification was only achieved with the type strain, C. jejuni NCTC 11168. This is 
believed to be due to difficulties in amplifying low %GC targets with the ExpandTM 
20 kb plus long template system (Roche). 
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Introduction 
1.1 General Background 
Campylobacter has been long recognized as a veterinary pathogen (Skirrow, 
1987); C. fetus is a cause of spontaneous abortion in cattle and sheep. Other 
members of the genus have been implicated in a variety of diseases in domestic 
animals including enteritis. Although, the first isolation was in 1833 (Nachamkin 
and Blaser, 2000) the characterisation of human Campylobacters did not begin in 
depth until 1957 (King, 1957). The link between Campylobacter and human enteritis 
was finally confirmed in 1977 by Skirrow, who used a mixture of vancomycin, 
polymyxin B and trimethoprim to inhibit other intestinal organisms in faeces 
obtained from patients with diarrhoea (Skirrow, 1987). 
The family Campylobacteraceae (part of the epsilon proteobacteria) has two 
other members, Arcobacter and Sulfurospirillum. Arcobacter spp. are becoming of 
increasing interest as they have been implicated in enteritis in humans and livestock, 
as well as, spontaneous abortion in livestock (Wesley, 1997). Sulfurospirilla have 
been isolated from oxidized marine sediment (Finster et al., 1997) and are not known 
to be pathogenic. The Campylobacteraceae are also closely related to 
Helicobacter and Wolinella (family Helicobacteraceae). Like Campylobacter and 
Arcobacter spp., the genus Helicobacter is a known pathogen of humans; H. 
pylori has been linked to formation of gastric ulcers (Wesley, 1997). Reclassification 
of members of Campylobacteraceae and Helicobacteraceae is ongoing, meaning that 
the previously non-pathogenic genus Wolinella now contains W. rectus (formally 
C. rectus), which is associated with gingivitis and peridonitis (Lai et al., 1992). 
Figure 1.1 shows the phylogeny of the Campylobacteraceae and some of the diseases 
caused by its members. 
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The campylobacters form the largest genus (fifteen species) and most are 
important veterinary or medical pathogens. Of greatest importance, medically, are C. 
jejuni and C. co/i; accounting for approximately 57 % and 3 % of food poisoning 
cases within England and Wales during 2004 (Health Protection Agency, 
http://www.phls.co.uk/infections/topics_azicampy/dataew.htm).  
1.2 C. jejuni as the causative agent in food-poisoning 
C. jejuni is the primary cause of bacterial enteritis worldwide, annually 
causing 3 to 4 times more cases than Salmonella (see Figure 1.2). The number of 
reported cases of C. jejuni steadily increased during the 1980's reaching a peak in 
2000. This is partially due to increased recognition by health services and better 
surveillance. Since 2000 the number of reported cases of both C. jejuni and 
Salmonella has fallen due to the increased emphasis on food hygiene education by 
the government. C. jejuni is a commensal of both chickens and pigs; consumption of 
improperly cooked chicken products is the major route of infection. Other routes 
include the consumption of unpasteurised milk, untreated water and contact with 
infected animals. During April and June 2001, the Advisory Committee on the 
Microbiological Safety of Food (ACMSF) sampled chicken products throughout the 
UK and found that 50 % were contaminated with Campylobacter c.f. Salmonella - 
5.7 % (ACMSF report, 2004). Of major concern is C. jejuni's ability to assume a 
'viable but non-culturable' (VNC) state, brought about by stress such as starvation. 
A number of bacteria are known to form VNC states including Salmonella enterica 
(Asakura et al., 2002), Salmonella typhi (Cho and Kim, 1999), 
C] 
Listeria monocytogenes (Besnard et al., 2000), Vibrio cholera (Shukia, 1995), 
H. pylon (Velazquez and Feirtag, 1999) and E. coli (Arana et al., 1997). 
Importantly, the VNC state of C. jejuni retains its infectivity (Stern et al., 1994); 
meaning that sentinel surveillance at food processing facilities may miss 
contaminated meat. Studies of C. jejuni VNC state cells has shown them to be more 
susceptible to a number of common disinfectants containing quaternary ammonium 
compounds or amphoterics used in the food industry. It is thought that this is due to 
degradation in cell membrane integrity during the transition from culturable to VNC 
states (Rowe et al., 1998). 
The infectious dose varies considerably, between 500 cells and 5 x 106  cells, 
depending on both the immune status of the individual and the manner in which the 
dose is ingested (Kothary and Babu, 2001). Infection is also characterized by flu-
like symptoms prior to the onset of diarrhoea, stomach cramps and occasionally 
vomiting. The flu-like symptoms are brought about by a severe inflammatory 
reaction during the initial infection stage. Diarrhoea is caused by the subsequent 
invasion of the epithelial cells by the C. jejuni and destruction of the epithelial lining. 
Like Salmonella and E. co/i the lipopolysaccharide/lipooligosaccharide of C. jejuni is 
toxic and thought to play an important role in the development several associated 
diseases (see below). Several toxins are produced by some strains but their 
contribution to the pathophysiology of C. jejuni is uncertain (Wasenaar and Blaser, 
1999). 
While not fatal in itself C. jejuni infection can lead to a number of extremely 
painful, debilitating and potentially life threatening diseases. Guillian-Barré 
syndrome (GBS) and its subset, Miller-Fisher syndrome (MFS), cause flaccid 
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paralysis and degradation of the autonomic nerve system. Hospitalisation is often 
required as the paralysis lasts for months and can lead to collapse of the respiratory 
system. Both GBS and MFS are caused by the demyelinization of nerves by the 
immune system. It has been shown that mimics of the gangliosides present on the 
surface of the nerves are present in some strains of C. jejuni (see 1.5.1). Other 
examples of C. jejuni associated disease are Henoch-Scholein purpura (potentially 
fatal), Irritable Bowel syndrome and Reactive Arthritis (both chronic and 
debilitating). The financial cost of C. jejuni enteritis is estimated at £ 587 per patient 
in the UK (Sockett and Pearson, 1987). 
The epidemiology of C. jejuni infections is interesting because it follows a 
seasonal distribution (Nylen et al., 2002) and can be accounted for by different 
cooking practices during the summer (e.g. barbecuing (Allerberger et al., 2003)). 
Cases tend to be sporadic in nature as person to person transmission is rare. 
Outbreaks of a large scale have been recorded and are usually due to an infected 
person improperly handling food (Fitzgerald etal., 2001). 
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Campylobacterjejuni (Human, food poisoning) 
Campylobacter Ian (Human, food poisoning/post-operative infection) 
Campylobacter coil (Human, food poisoning) 
Campylobacter upsailensis (Dogs, commensal associated with 
diarrhoea] disease in dogs and humans) 
Campylobacter helveticus (Dogs) 
Campylobacter fetus (Type species, Sheep and Cattle, Spotaneous 
abortion) 
Campylobacter hyointestinalis (Human) 
Campylobacter mucosalis (Human) 
Campylobacter concisus (Human) 
Campylobacter curvus (Human) 
Campylobacter showae (Human) 
Campylobacter rectus (Human, peridontal disease) 
Campylobacter sputorum (Cattle, Sheep and Human) 
Campylobacter graciils (Human) 
Bacteroides ureolyticus 










Helicobecter pylon (Human, gastric ulcers) 
Woilnella succinogenes 
Bus'*holderia cepacia 
90 	 100 
Figure 1.1 Phylogenetic tree of the family Campylobacteraceae, based upon 16S rRNA 
sequence homology; including the close relatives Helicobacter pylori and WoIineIIa 
succino genes. Hosts are shown and associated diseases (if known and confirmed). 
Burkholderia cepacia is included as an outgroup organism (adapted from Nachamkin 















1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 20M 2001 2002 2003 2004 
Year 
Figure 1.2 Graph showing the number of isolations reported to the Health Protection 
Agency (in England and Wales) of Campylobacterspp. (blue line) and Salmonella spp. 
(red line) during the period 1986 to 2004. 
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1.3 C. jejuni genomics 
C. jejuni NCTC 11168 was the second pathogenic organism to be sequenced 
by the Sanger Institute and was completed in 2000 (Parkhill et al.). The decision to 
sequence this strain was made because it was hoped that the genome sequence would 
explain some interesting observations on the capability of C. jejuni to produce toxins 
(Wassenaar and B laser, 1999). The genome size was determined to be 1.64 Mb and 
encoded 1654 putative genes, making it one of the densest genomes sequenced (see 
Table 1.1 for a comparison with other related bacteria). It was also unusual as no 
insertion sequences or phage associated sequences were found. 
A second strain of C. jejuni, RM1221, was sequenced by The Institute for 
Genomic Research (TIGR) and completed in 2004 (Fouts et al., 2005). It was hoped 
that comparison of the two genomes would show differences that influenced host 
range as NCTC 11168 was a human isolate and RM 1221 was isolated from a 
chicken carcass. However, the genomes showed an extremely high degree of 
synteny (see Table 1. 1), the only differences being the presence of 4 phage associated 
sequences in RM 1221 and differing capsular polysaccharide (CPS) gene 
complements. Both genomes include homopolymeric tracts of guanidine and 
cytidine thought to be important in protein expression as mechanisms for phase 
variation. The tracts are clustered within the loci for lipooligosaccharide (LOS), CPS 
and flagella biosynthesis, all of which are important recognition factors for the host. 
N. 
Species Wolinella Helicobacter C. jejuni C jejuni C. coil C. larl C. upliensis 
succinogenes pylori 
Strain DSM 1740 26695 NCTC 11168 RM1221 RM2228 RIM 2100 IiM3195 
Host BoAne Human Human AAan AAan Aian Canine/Feline 
Senome Size (bp) 2 110 355 1 667 867 
1 
1 641 481 1 777 824 -1.68 Mb -1.5 Mb 1.66 Mb ;c content (%) 48.5 39 30.6 30.3 31.4 29.6 34.5 
Open reading frames 11 Predicted number 2046 1 552 1 654 1 882 -1771 -1 558 -1793 
Flexible genome pool 
Reported plasmids 0 0 0 0 1 1 2 
Phages and phage-like elements 1 0 0 4 Unknown Unknown Unknown 
IS elements 2 2 0 0 5 0 0 
Genomic islands 2 1 0 0 Unknown Unknown Unknown 
Table 1.1 Comparison of C. jejuni sequenced strains to related bacteria. C. co!i,C. lari and C.upallensis are currently being sequenced and so all 
data is based on the most current contigs available. 
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1.4 Outer membrane proteins of C. jejuni 
Outer membrane proteins of C. jejuni have been studied by several methods 
as a means to elucidating its pathophysiology and identifying possible vaccine 
candidates (Blaser et al., 1983 and 1984. Dunn et al., 1987). In 1991, Pei, Ellison 
and Blaser purified four outer membrane proteins (named PEB5) that had been 
previously identified by immunoblotting of glycine extracts from C. jejuni whole 
cells (B laser and Duncan, 1984). Each of the PEB proteins were of molecular 
weight, PEB 1 28 kDa, PEB2 29 kDa, PEB3 30 kDa and PEB4 31 kDa and dominant 
proteins in glycine extracts. However, the function of these proteins remained 
unknown. 
Both PEB 1 and PEB4 were identified as being able to bind to the surface of 
HeLa cells (Kervella et al., 1993). The same study showed that PEB4 is not surface 
exposed and so therefore, its ability to bind to eukarytotic cells is a secondary effect. 
PEB1 was shown to be surface exposed and later shown to be a major binding factor 
for C. jejuni cells (Pei et al., 1998). 
1.5 Sugar structures in C. jejuni 
1.5.1 Lipopolysaccharide or Lipooligosaccha ride 
The schemata of a Gram-negative cell wall is shown in Figure 1.3. The inner 
membrane comprises a lipid bilayer with proteins embedded or associated with either 
the periplasmic or cytoplasmic surfaces. The outer membrane consists of two 
leaflets; the inner leaflet is composed of unmodified lipids (as in the inner 
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membrane) and the outer leaflet of modified lipids (mainly lipid-A). The outer 
membrane also has proteins embedded and associated with its periplasmic surface. 
The major constituent of the outer membrane's outer leaflet is lipopolysaccharide 
(LPS). LPS is a polysaccharide chain embedded in the outer membrane by lipid-A. 
The polysaccharide chain consists of an inner core which has a constant structure, an 
outer core that is moderately variable and an 0-chain made of repeating units of 
polysaccharides. A number of mucosal pathogens, including C. jejuni, produce a 
structurally related compound Los; which lacks the polymeric 0-chain. 
The biosynthetic pathway for LOS and LPS is identical and conserved across 
the Gram negative bacteria. Lipid-A was thought to be essential for all Gram 
negative bacteria, but it has been shown that Neiserria meningitidis is able to survive 
without (Bos and Tommassen, 2004). LPS is manufactured in the cytoplasmic leaflet 
of the inner membrane. The first step in synthesis is the addition of a 14-acyl chain 
to UDP-G1cNAc by LpxA. The acetate side chain is then removed by LpxC and 
replaced by a 14-acyl chain by LpxD to form UDP-2,3-diacylglucosamine. In E. coli 
and Salmonella LpxH then cleaves the UDP-side chain at its pyrophosphate bond to 
form 2,3-diacyiglucosamine (see Figure 1.4). An orthologue of LpxH does not exist 
in C. jejuni, however, it is likely that there is another as yet unidentified enzyme. A 
dissaccharide is then produced by LpxB linking UDP-2,3-diacylglucosamine and 2,3-
diacyiglucosamine. The 4' position of the dissaccharide is then phosphorylated by 
LpxK to produce Lipid IVA. Before Lipid-A sysnthesis can proceed any further, the 
first inner core residue 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo), must be 
attached. The number of Kdo residues attached is species specific; C. jejuni attaches 









residues. Kdo is attached by KdtA (also called WaaA) and the KdtA amino acid 
sequence is conserved across the Gram negative bacteria. The mechanism which 
controls the number of attached Kdo residues is not known. The final stage of Lipid-
A synthesis is the attachment of two acyl chains to the disaccharide (see Figure 1.5). 
These terminal acyltransferases require Kdo in their substrate for activity. The length 
of each acyl chain is species specific. 
Figure 1.3 Schematic of the Gram negative cell wall showing 1-Porin 2- Capsular 
polysaccharide 3-Lipopolysaccharide 4-Peptidoglycan 5-Periplasmic protein 6-
Transmembrane protein 7-Membrane associated protein 8-Cytoplasmic proteins 
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Figure 1.4 The first four steps of lipid-A synthesis in E. coil. Initially, a 14-carbon acyl 
chain is added to UDP-GlcNAc by LpxA. The acetate side chain is the removed by 
LpxC to allow the addition of a second 14-carbon acyl chain by LpxD. Finally, the 
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Figure 1.5 The final six steps in Lipid-A biosynthesis by E. coli. A diasccharide is formed by LpxB and phosphorylated by LpxK. Two 
Kdo residues are then added to the disaccharide by HdtA. The final steps are the addition of two acyl chains by LpxL and LpxM. 
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Synthesis of the core saccharide proceeds sequentially, beginning with the 
addition of L-glycero-D-manno-heptose (G-ManHep) by WaaC (see Figure 1.6). A 
second G-ManHep residue is then attached by WaaF to complete the inner core. The 
length, order of residues, number of side chains and position of side chains is strain 
specific and is determined by both gene complement and by regulation of expression. 
The LOS biosynthetic locus in C. jejuni was located by Wood et al. (1999), they 
probed a chromosomal library of C. jejuni NCTC 11168 and NCTC 11351, with a 
32P-labelled fragment of a wbaP (WbaP initiates 0-chain synthesis Salmonella). A 
single plasmid from each strain library, positive for wbaP by Southern hybridization, 
was sequenced and a partial LOS locus was obtained. Further analysis of the locus 
from eight strains by Gibert et al. (2002) found three structurally related loci (see 
Figure 1.7). The differences between the loci classes, explains the extremely variable 
structure of C. jejuni LOS. Importantly, all three classes contain cst which is 
responsible for the attachment of N-acetylneuramic acid (NeuNAc). NeuNAc is not 
commonly found in bacteria and is responsible for the structural similarity between 
C. jejuni LOS and mammalian gangliosides. 
Gangliosides are a sialic acid containing subset of glycosphingolipid (GSL), 
found on the surface of neurons. GSLs are found on the surface of every cell and 
their function has not yet been determined, but they are thought to play roles in 
morphogenesis, cell differentiation (Hakomori, 1984) and cell adhesion (Philips et 
al., 1990 and Walz et al., 1990). During an immune response to C. jejuni infection 
the structural similarity of the LOS and gangliosides can lead to an autoimmune 
reaction. In particular, anti-GM(1) has been linked with the onset of GBS and 
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MFS (see 1.2). 
Phase variation plays an important role in the structure of the expressed LOS. 
C. jejuni 0H4384 possesses a class B locus (see Figure 1.7) and therefore two copies 
of cst. The expression of cst-I can be switched on/off by strand slippage in a 
homopolymeric tract that will cause premature termination of translation. 0H4384 
can therefore change the number of and position of NeuNAc residues by switching 
cst-I on and off. If cst-J is on, a long LOS which mimics GT1a is produced. When 
cst-I is switched off, cst-II is switched on and produces a short LOS that mimics GDI 
(see Figure 1.8 (Gilbert et al., 2000)). 
Once synthesis of the LOS molecule is complete, it is transported across the 
membrane by an ABC transporter (MsbA in E. coil). The mechanism by which LOS 
is transported across the perplasmic space is unknown. Two hypotheses have been 
suggested (see Figure 1.9); the first is that a soluble chaperone binds the lipid-A and 
allows passage across (Bos and Tommassen, 2004) and the second, that transport 
occurs at a site of direct contact between the two membranes (Bayer junctions 
(Leive, 1977)). The final step is for a flippase (Imp in E. coil) to flip the LOS from 














• ManDAc 	Gal 	* SedHep 	 Lipid-A 
• CMP-NeuNAc Hex 	• ADP-G-ManHep(D) 
• GaINAc 	4' G-ManHep • Q NeuNAc 	Kdo 
Figure 1.6 Putative synthetic pathway for the LOS inner and outer core in C. jejuni NCTC 11168; showing the synthetic pathways for 
the precursors of G-ManHep and NeuNAc (adapted from Linton etal., 2002) 
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Class "A" (11.5 kb) 
* 	G 	 G 
I 	 L IIILiiiiI 
	
Class "B" (12.4 kb) 
N 	 I 
	
Class "C" (13.5 kb) 
Figure 1.7 Schematic showing the 3 classes of LOS loci arrangements found in C. jejuni. Genes are colour coded to indicate function. 
The * indicates where a premature translation stops are observed in some strains. The G indicates the position of a poly(G) tract. The 
genes orflO (dark green) and 0,111 (olive green) are unique to class "A" and "B" loci. Three genes (offl4, 15 and 16) are unique to 
class "C" loci. Cst (dark blue) is found in all three classes but class "A" only has one copy, class "B" two copies and in class "C" it is 
as an in-frame fusion with CMP-Neu5Ac synthase, o10 (adapted from Gilbert etal., 2002). 
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Figure 1.8 Schematic to show the effect of turning expression of cst-I on/off on the 














Figure 1.9 Proposed methods for the transport of LOS from the cytoplasm to the outer 
leaflet of the outer membrane. A: The completed LOS molecule is transported across 
the inner membrane by MsbA. A soluble chaperone then transports the LOS molecule 
across the perplasm to the outer membrane. The LOS is then flipped across the 
outer membrane; by Imp. B: The completed LOS molecule is transported across the 
inner membrane by MsbA. The LOS molecule then moves via a point of direct contact 
between the the inner and outer membranes (Bayer junction, indicated in orange). 
Imp then flips the LOS molecule across the outer membrane (adapted from Bos and 
Tommassen, 2004) 
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1.5.2 Capsular polysaccharide 
Until 2000, the presence of a capsule structure on the surface of C. jejuni was 
unconfirmed. The usual methods of capsule detection (e.g. India ink) did not work as 
the capsule is very thin. In 2000, Karlyshev et al., analysed the genome sequence of 
C. jejuni and demostrated with gene knockouts that C. jejuni possessed structures 
similar to the K-antigens of E. co/i and Salmonella (Group II Gram-negative 
capsules, see below). Final confirmation was obtained when Karlyshev etal. (2001) 
was able to stain and visualise the capsule with Alcian blue, using electron 
microscopy. 
Comparison of the capsular polysaccharide (CPS) genes across the Gram-
negatives has been hampered by a non-consistent nomenclature. In 1996, Reeves et 
al., proposed a system for naming the sugar transferases found in the capsular 
polysaccharide loci of E. coli and Salmonella. Subsequent comparison of the loci 
revealed that four arrangements of genes are found but an overlying structure to all 
four groups exists. In all cases, the genes responsible for the ABC-transporter system 
flank the sugar transferases. 
CPS is composed of a lipid modified with undecaprenol and a polysaccharide 
chain. The synthesis pathway and locus structure is conserved throughout the Gram 
negative bacteria. Synthesis of the modified lipid and the polysaccharide chain 
occurs separately within the cytoplasm (see Figure 1.10). 
KpsU carries undecaprenol-CMP to the KpsC which uses it for modification 
of a lipid in the inner leaflet of the cytoplasmic membrane. The modified lipid is 
then transported across by the Kps ABC transporter system. The polysaccharide is 
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synthesised by the sequential addition of sugar residues to a Kdo-modified lipid in 
the cytoplasmic leaflet. The composition and structure of the chain is determined by 
gene expression and complement. On completion the polysaccharide chain is 
transported across by the Kps ABC transporter system. It is not yet known when the 


















Figure 1.10 Schematic of the capsular biosynthesis pathway in E. coil. Kdo-CMP is 
transported to KpsC by KpsU; where the Kdo residue is attached to a lipid in the inner 
membrane. The polysaccharide chain is synthesised separately on a modified lipid 
within the inner membrane by KfiA, B, C and D. Both the modified lipid and the 
polysaccharide chain are transported across the inner membrane by the ABC-
transporter KpsS,T and M. It is not known whether the polysaccharide chain is 
attached to the modified lipid before, during or after transport. Transport across the 
outer membrane is achieved via porin. 
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1.5.3 Post-translational modification of protein 
Post-translational modification of proteins with glycans is the most common 
form of modification seen in eukaryotic organisms (Nita-Lazar et al., 2005). Until 
recently, this form of modification was believed to be exclusive to eukaryotes and 
archaea. An increasing number of pathogenic bacteria have been found to 
glycosylate surface exposed proteins (Power and Jennings, 2003). 
1.5.3.1 0-linked glycosylation 
0-linked glycosylation has been found in a number of bacterial species: 
Pseudomonas aeruginosa, Caulobacter crecentus, Aeromonas caviae, H. pylori and 
Neisseria spp. Glycosylation of Campylobacter flagellum was first reported in 1989 
by Logan et al. Non-glycosylated flagella have been shown to cause an apparent 
decrease in motility, adherence and invasive capability (Szymanski et al., 2002). 
Analysis of the glycan moieties present on flagella have shown the presence 
of pseudaminic acid or an acetamindino subsituted analogue of pseudaminic acid (see 
Figure 1.11) (Thibault et al., 2001). The glycans are attached within a region of 19 
serine and theronine residues within the central hydrophobic region of FlaA or FlaB. 
Attachment is not dependent on a recognition sequence (c.f. N-linked glycosylation 
(see 1.5.3.2)) but is dependent on the tertiary structure of the protein (Karlyshev et 
al., 2005). The number and type of residues attached to the flagella subunits is 
thought to be both species and phase variable (Karylshev et al., 2005). 
The genes associated with 0-linked glycosylation are co-located with the 
flagella biosynthesis locus. The glycosylation locus contains - 50 genes and shows a 
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high degree of variability between species (Karlyshev et al., 2005). Mutation of the 
genes with the glycosylation locus affects expression and assembly of the flagellar 
apparatus. Importantly, mutations that prevent glycosylation cause the accumulation 
of unmodified subunits in the cytoplasm (Goon et al., 2003); suggesting that 
glycosylation of the subunits is require for recognition by the flagella 
secretion/assembly apparatus (Karlyshev et al, 2005). 
OH 	 COOH 
H3C 
5,7-Diacetamido-3, 5,7, 9-tetradeoxy-L-g/ycero-L-manno-nonulsonic 
acid 
OH 	 COOH 
Ser 
7-Acetamido-5-aceti midoyl-3, 5,7, 9-tetradeoxy-L-g/ycero-L-manno-nonulosonic acid 
Figure 1.11 Structure of two pseudaminic acid derivatives found attached by the 0-
linked glycosylation systems of Gram negative bacteria. Ac - acetyl Am - acetimidoyl 
(adapted from Schmidt etal., 2003) 
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1.5.3.2 Winked glycosylation 
The N-linked protein glycosylation pathway is highly conserved in 
eukaryotes (Nita-Lazar et al., 2005); comparison of putative genes from C. jejuni 
revealed a homologue of stt3 the most highly conserved protein in the pathway 
(Wacker et al., 2002). So far 21 proteins have been isolated from C. jejuni in 
glycosylated forms (Szymanski et al., 2003). 
The glycosylation pathway can be split into two events: 1. the assembly of a 
lipid-linked polysaccharide in the inner membrane, and 2. the transfer of the 
preassembled oligosaccharide to the protein and attachment at the N-X-S/T motif. 
The conservation of the pathway between C. jejuni and eukaryotes is extremely high 
with only the complexity of the polysaccharide being different. The assembly of the 
polysaccharide occurs in a stepwise fashion by the addition of single sugar units to a 
lipid carrier in the inner membrane (see Figure 1.12 and Figure 1.13) by the enzymes 
Pg1A, C, H, I and J, plus two unidentified enzymes; resulting in a branched 
heptasaccharide, Ga1NAc2(Glc)GalNAc3Bac. The completed glycan is then flipped 
across the membrane and attached to an asparagine residue in the motif N-X-S/T 
(where X is any amino acid except proline) by the Stt3 homologue - Pg1B (see 
Figure 1.13). Recent experiments with E. coli transformed with the 
C. jejuni glycosylation apparatus have shown that the N-X-S/T motif is not the only 
requirement for glycosylation. Nita-Lazar et al. (2005), showed that there is also an 
(as yet unidentified) structural requirement for glycosylation and this likely to be 
associated with the way in which the target protein is transported across the inner 
membrane. 
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Figure 1.12 Schematic of the biosynthesis of the Winked glycan in C. jejuni. Arrows 
indicate the residue added by the indicated g lycosyltra nsfe rase (adapted from Linton 
etal., 2005) 
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Figure 1.13 Model of N-glycan synthesis in C. jejuni and a comparison of the N-glycan 
structure from Saccharomyces cerevisiae. Sugar resdiues are added sequentially to a 
lipid carrier by the Pgl glycosyltransferases. PgIB then flips the N-glycan across the 
membrane into the periplasm and attaches the glycan to the protein at the N-X-SIT 
motif. In S. cerevisiae, the glycan is synthesised in the same fashion but after being 
flipped into the ER lumen is further modified. The PglB homologue, Stt3 then attaches 
the N-glycan to the nascent protein (adapted from Szymanski et al., 2003) 
1.6 Typing methods used with Camp ylobacter spp. 
1.6.1 Serotyping 
1.6.1.1 Penner 
The Penner serotyping systen was first described in 1980 (Penner and 
Hennessy, 1980). The system uses sensitised erythrocytes and antisera, raised 
against heat-stable antigens, to type isolates by passive agglutination. The exact 
nature of the serodeterminant was unknown until 1996 when Chart et al. showed that 
Penner antisera did not recognise LOS (via immunoblotting) but did recognise 
antigenic material extracted from the cell envelope at 50 °C. Previous reports had 
shown that CPS could be extracted from E. coil at low temperatures (Orskov and 
Orskov, 1989). CPS was confirmed as the serodeterminant by Karlyshev et al., using 
mutants in kpsM, S and C which were deficient in CPS production (Karlyshev et al., 
2000). 
Penner serotyping is the most commonly used non-genomic based typing 
scheme; due to its high level of simplicity and repeatability between typing labs (c.f. 
Lior serotyping (see 1.6.1.2) and fla-RFLP (see 1.6.4)). Initially, 24 Penner 
serotypes were described including both C. jejuni and C. coli (Penner and Hennessy, 




The Lior serotyping system is a rapid slide agglutination protocol that uses 
heat-labile antigens to raise antisera (Lior et al., 1982). The exact nature of the 
serodeterminants in this system is not known, but there is some evidence that the 
flagella may be important (Aim etal., 1991). The heat-labile nature of the antigens 
has made standardisation difficult between different laboratories; as a slight variation 
in protocol can produce major variations in serotype detected. 
1.6.2 Multi-locus Sequence Typing 
Multi-locus sequence typing (MLST) is a similar technique to multi-locus 
enzyme electrophoresis (MLEE) where the mobility of conserved 'housekeeping' 
enzymes is compared. In MLST, it is the DNA sequence of housekeeping genes 
rather than enzymes being compared, making it highly discriminatory and 
reproducible. In C. jejuni, MLST has been performed using the genes adk, aspA, 
Cj1585c, ginA, gitA, glyA, ilvD, mdh, pgi, pgm, 1ki and uncA (Manning etal., 2003). 
Two schemes exist for MLST of C. jejuni, scheme A, those genes indicated in bold, 
was selected after the completion of the C. jejuni NCTC 11168 genome in 2000 
(Dingle et al., 2002). Once each gene has been sequenced comparisons of each gene 
between strains is used to assign sequence types (ST). 
MLST is highly reproducible and is widely used on a number of organisms. 
Primers and genes used with each organism has been standardised internationally and 
an MLST profile database set up (http:\\www.mlst.net ). 
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1.6.3 Pulsed Field Gel Electrophoresis 
Pulsed field gel electrophoresis (PFGE) is considered to be the 'gold standard' 
for molecular techniques (Olive and Bean, 1999). For PFGE whole bacterial cells are 
combined with molten agar and allowed to set in plastic molds. The resultant plugs 
are treated to lyse the cells and destroy any proteineous material. Extensive washing 
steps remove any debris before restriction with an infrequently cutting restriction 
enzyme. The plugs are then inserted into an agarose gel and subjected to 
electrophoresis in a changing electric field. The electric field is manipulated so that 
both the polarity, the angle of the field relative to the gel (for some PFGE subtypes 
only) and the time for each change (switch time) maximises the separation between 
fragments. Restriction patterns can then be visualised using ethidium bromide 
staining. 
The restriction fragments obtained in this method are very large, typically 
30 kb to 2 Mb. Restricting whole genomic DNA in an agarose plug, stabilises the 
fragments and prevents shearing due to mechanical stress. The large fragment size 
also affects the mobility of the DNA within an agarose gel. The changing electric 
field causes DNA to reorientate, small fragments reorientating and migrating faster 
than larger, exaggerating the difference in size (see Figure 1.14). As switch time 
increases the larger fragments have more time to reorientate and migrate through the 
gel. 
PFGE has been used successfully on many bacterial species including E. coil 
(Arbeit et al., 1990), Stapylococcus aureus (Saulnier et al., 1993), 
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Figure 1.14 Diagrammatic representation of the movement of DNA molecules through the agarose matrix of a PFGE gel. Arrows 
indicate the direction of the electric field. A - When the electric field direction is changing quickly (short switch time) large fragments 
are unable to reorient themselves before the electric field changes direction. Short fragments are able to reorient quickly and move 
through the gel matrix. B - As the time spent at each field direction increases (long switch time) the large fragments are able to 
reorient and move through the gel matrix. 
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1.6.4 Restriction Fragment Length Polymorphism 
Restriction fragment length polymorphism (RFLP) involves visualisation of 
whole genome restriction fragments by electrophoresis, Southern blotting and 
probing for specific gene sequences. This technique has been successfully used to 
type Ps. aeruginosa (Loutit and Tompkins, 199 1) and Legionella pneumophila (Tram 
et at., 1990). The complexity of RFLP patterns is dependent on the restriction 
enzyme and probe combination. Ribotyping, a variation of RFLP, uses probes 
against 16S and 23S rRNA genes and has been used extensively for typing C. jejuni 
and Helicobacter spp. (Moore et at., 2002, and Vos et at., 1999). 
More recently the use of PCR in place of Southern blotting and probing has 
become the preferred method. PCR-RFLP of the 16S rRNA gene in Campylobacter 
spp., Arcobacter spp. and Helicobacter spp. has been shown as discriminatory as 
RFLP (Marshall et al., 1999). Other PCR-RFLP techniques for typing C. jejuni have 
been studied with particular emphasis on fla-RFLP. Fla-RFLP uses primers for the 
flanking conserved regions of theflaA gene and typically the restriction enzyme DdeI 
(Heitt et at., 2002, Mohran et al., 1996, Nishimura et al., 1996). Several variations 
on this technique including amplification of both flaA and flaB (Petersen and Newell, 
2001) or more discriminatory electrophoresis (Hein et al., 2003) have been 
developed in an effort to increase the techniques discriminatory power. 
1.6.5 Amplified Fragment Length Polymorphism 
Amplified fragment length polymorphism (AFLP) was first described in 1995 
by Vos et at. Since then it has been used to type a large number of organisms 
including both eukaryotes (Rubio et at., 2000) and prokaryotes (Peters and Threlfall, 
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2001 and Valsangiacomo et al., 1995). The technique is similar to RFLP, whole 
genomic DNA is digested with one or two restriction enzymes; restriction site 
specific adaptors are then ligated to the restriction fragments. Restriction patterns are 
visualised by amplifying the restriction fragments with primers specific for the 
adaptors and separation of the fragments by electrophoresis. A major advantage of 
AFLP over other techniques is the use of the restriction site specific adaptors. The 
use of adaptors as priming sites means that no previous knowledge of the genomic 
sequence is required and the same adaptors can be used with multiple organisms. 
Visualisation of restriction patterns is primarily achieved by the use of 
fluorescently labelled primers and sequencing machines. Changes in the primer 
design are used to decrease the number of restriction fragments visualised; typically 
the addition of selective bases to the 3' end of the primer or only labelling one primer 
in multi-restriction enzyme protocols (Duim etal., 2001). 
Typing of C. jejuni with the protocol first described by Vos (1995) has been 
extensively carried out on large sets of Campylobacter spp. isolates; both clinical and 
non-clinical in nature (Broman et al., 2000, Desai et al., 2001, Duim et al., 1999, 
2000 & 2001, On and Harrington, 2000). However, optimisation of the restriction 
enzyme set used for C. jejuni typing has not been carried out. 
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1.7 Monoclonal antibodies and their uses 
Polyclonal antibodies are obtained after challenge of an animal (usually 
sheep, horse or rabbit) with the target antigen. After booster challenges the animal is 
bled and serum extracted from the bleed. This gives a small amount of an undefined 
antibody mixture. Repeated bleeds can be taken but animal welfare considerations 
must be taken into account, as well as, the changing nature of the antibody mixture 
obtained. 
Monoclonal antibody (mAb) preparation allows continuous production of one 
Ab with defined specificity and affinity. mAbs are of most use where repeatability is 
important; consequently they are used in a variety of diagnostic techniques such as, 
Enzyme linked immuno-sorbent assay (ELISA), Immuno-fluorescent assays (IFA), 
Western blotting and protein arrays. The use of mAbs as therapeutic agents has met 
with some success, problems with toxicity and immune-suppression of the patient, 
however, prevented widescale production (Glennie and Johnson, 2000). Recent 
advances in production and a new understanding of human genomic sequences now 
allow for the production of human mAbs from engineered mice or phage display 
(Vaughan etal., 1998). 
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1.7.1 Systems for producing monoclonal antibodies 
1.7.1.1 Hybridoma-based systems 
The first monoclonal antibodies were created by Kohler and Milstein, 1975. 
They fused spleenocytes and myelomas using Sendai virus. Since these first 
experiments the fusion methods have been refined to include electroshock (Lo et al., 
1984) and polyethylene glycol (PEG) mediated fusion, with PEG mediated fusion 
being the most commonly used. However, the exact method by which cells fuse 
when PEG is used is currently unknown and it is also not known if it is PEG or a 
molecule that co-purifies that mediates fusion. 
There are several different mouse myeloma cell lines avilable including P3-
X53-Ag8, SP2/0' and their derivatives. It is possible to fuse myeloma cells from a 
species different to the species that the splenocytecs are harvested from but the 
resultant hybridomas are less stable. The basic myeloma cell lines are usually 
'producing' cell lines. 'Producing' cell lines contain the loci that encode antibodies 
from the species in which the myeloma was created. Hybridomas created using these 
cell lines may therefore produce non-functional or non-specific Ab. 
Derivatives of the basic cell lines e.g. SP2/0'-Ag14, have been produced by 
selecting for cells that show beneficial characteristics such as increased growth rate, 
robustness and commonly 'non-producing'. 'Non-producing' cell lines lack the loci 
encoding the antibodies; thereby increasing the efficiency of fusion as all Ab 
producing hybridomas will produce Ab specific for the target Ag 
(Fazekas de St Groth and Scheidegger, 1980). 
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Hybridoma production can be split into four stages (see Figure 1.15): 1. 
production of splenocytes and myelomas 2. fusion 3. selection and 4. propagation. 
The first two stages depend upon the myeloma cell line, the antigen and the species 
used for splenocyte production. Selection and propagation are common to all 
hybridoma protocols. Selection is achieved by the use of the hypoxanthine guanine 
phosphoribosyl transferase (HGPRT) salvage pathway and the alternative thymidine 
salvage pathway. Growth media is supplemented with hypoxanthine, thymidine and 
aminopterin. Aminopterin blocks the manufacture of GTP and TTP (see Figure 
1.16), and consequently RNA and DNA in unfused myeloma cells; splenocytes 
possess the HGPRT salvage pathway but are unculturable. Fused cells possess the 
culturable nature of the myelomas and the HGPRT salvage pathway from the 
spleenocytes; consequently fused cells are able to replicate and grow. Once all of the 
unfused cells have died, selection is gradually relaxed so that fused cells can revert to 
the normal GTP and TTP synthesis pathways. 
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Figure 1.15 Schematic of the hybridoma formation process. 	Splenocytes are 
harvested from a challenged mouse and fused with myeloma cells. Unfused cells are 
killed by the addition of HAT to the culture medium. Fused cells are tested for the 
production of antibody against the target and if positive propagated by limiting 
dilution. After three rounds of limiting dilution the resultant colonies are clonal and 
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Figure 1.16 The dTTP and dGTP biosynthetic pathways. HAT selection supplements 
the culture media with hypoxanthine, aminopterin and thymidine. Aminopterin 
prevents the synthesis of dTMP and 5-formido imidazole-4-carboxamide 
ribonucleotide (*)• Consequently preventing formation of dTTP and dGTP. Fused 
cells posses HGPRT and so are able to use the alternative pathway for the synthesis 
of dGTP. The supplement of thymidine in the media allows dTTP synthesis. Unfused 
cells are unable to replicate and die. 
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Propagation is essential to hybridoma production as they are inherently 
unstable. After fusion, the hybridomas possess double the normal amount of genetic 
material for a cell. In this situation the cell stabilises by allowing chromosomes to be 
lost. The order in which chromosomes are lost is random for each culture. After 
three rounds of propagation hybridomas become more stable and the likelihood of 
losing antibody production lessens. Propagation is also important as it is the means 
of splitting a possible mixture of Abs into mAbs. As soon as a positive culture is 
identified it is diluted and split (limiting dilution). After a further two dilutions/splits 
if 99% of the resultant cultures are negative for antibody production, statistically, the 
I% producing antibody will represent single clones. 
1.7.1.2 Phage display 
Phage display is a highly versatile system for the screening of proteins that 
possess the ability to bind to a target protein. Phage display works by fusing a protein 
of interest or more commonly a library of proteins to the phage coat protein pill. 
Phage containing this fusion are then used to infect E. co/i where the protein fusion 
can be expressed. mAbs were first expressed as phage fusion by Breitling et al. in 
1991. A single chain variable fragment was cloned into a phagemid based upon the 
genome sequence of fdtet. Since this initial experiment phagemid vectors have been 
designed to increase the efficiency of cloning, display and expression of Ab-pill 
fusions (McCafferty et al., 1990 and Smith, 1985). An example of such a phagemid 
is shown in Figure 1.17 and some of the antibody display formats in Figure 1.18. 
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Figure 1.17 Map of a phagemid carrying a co-expressed Ab light chain and heavy 
chain-gene Ill fusion. VL = Variable region of light chain CL = Constant region of light 
chain VH = Variable region of heavy chain CHI = First constant region of heavy chain P 
= Promoter region S = Start of transcribed region. 
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Figure 1.18 Representations of the antibody formats that are currently possible using phage display as a production method. The 
bottom row represents bispecific antibodies i.e. target more than one antigen. VH - Variable heavy domain CH —Constant heavy domain 




To optimise the AFLP typing system using the published sequence of 
C. jejuni NCTC 11168. 
. To devise a novel typing system based upon the CPS locus that will: 1. 
combine the simplicity and speed of RFLP and 2. harmonise DNA-DNA 
based typing systems with Penner serotyping. 
. Clone the suspected outer membrane protein PEB3, raise monoclonal and 
polyclonal antibodies against it for use in an immunomagnetic separation 
system. 
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Materials and Methods 
2.1 Health and Safety 
Throughout the project each protocol was assessed before it was carried out 
according to the University of Edinburgh guidelines, which conform to the Health and 
Safety at Work Act. At all times care was taken to use reduce the risk to everyone who 
would come into contact with material used in each experiment. Where potentially 
hazardous material was used personal protective equipment appropriate to the risk 
involved was worn. The used of genetically modified organisms was approved, before 
being performed, by the departmental board according to the relevant legislation. At all 
times care was taken to ensure that genetically modified organisms were not released 
into the environment. In all the experiments involving the use of animals, Home Office 
permission was obtained and the work carried out according to the specifications of each 
project license. In all cases material was disposed of in an appropriate manner. 
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2.2 Materials used 
2.2.1 Primers and plasmids 
The primers used in this work are detailed in Table 2.1 and the plasmids in 
Figure 2.1 and Figure 2.2. 
Name Target Sequence Source 
Cjl430Fwd cj1430 ATGGCAATAGAATTTGATATACAAG Karlyshev etal., 
2005 
Cj 1 43ORev cjl 430 GCAAGAATATCGCGATCGGAAAGAAT7GGCG Karlyshev et al., 
2005 
hddCFwdc hddC GCCGCCACAAAGTATTATTGCTTGCAA Karlyshev et al., 
2005 
gmhA2Fwd gmhA2 ATGGAGAATTTAAATTCCTATATAAAAGG Karlyshev et al., 
2005 
ak186 kpsF GAAAAGGAAGCTTGTCCTTTGCAGCTTGC Karlyshev etal., 
2005 
KpsD-SFwd kpsD CGTTAATGCTCCAGGACTTTATCATGGC7T This project 
KpsD-SRev kpsS CCTTAGTCGGACAGCCTTCTAZAAATAGCACT This project 
FclFwd FcI TAGCGGGGCACAAAGGAAC This project 
FclRev FcI CAATCCATAAGTCTATCCATTGTGC This project 
KpsSFwd kpsS CCTAGCGGAACGAGGTGTAAGTGTG This project 
KpsSRev kpsS GTCGGACAGCCTTCTAAAATAGCAC This project 
PEB3Fwd peb3 CATATGACGGCCTTAAAAGATATAG This project 
PEB3Rev peb3 GGATCCAAATCTTGTGTTTCTTTGCTCG This project 
EcoRlAdapi CTCGTAGACTGCGTACC Vos etal., 1995 
EcoRlAdap2 ATTGGTP.CGCAGTCTAC Vos et al., 1995 
EcoRlPr EcoRlAdap GACTGCGTACCAATT Vos etal., 1995 
Table 2.1 Table of the primers/oligonucleotides and their sequence sources; used 
throughout this project. All primers were diluted to 100 pM for stock solutions and to 10 
pM for lOx working solutions in 0.5 M Tris pH 8.0 and stored at -20 °C. 
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Figure 2.1 Schematic of the plasmid pET-16b (Novagen) showing the location of the 
His.Tag sequence. The multiple cloning region is situated between the His-tag and Factor 
Xa site. 
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Figure 2.2 Schematic of the plasmid pGEM-T/-Easy (Promega) showing the location of the 
multiple cloning site and its position in relation to the lac operon. The two vector version, 
-T and —TEasy, are identical except for the number of restriction sites in the multiple 
cloning region. 
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2.2.2 Bacterial strains 
The bacterial strains used in this work are detailed in Table 2.2 and Table2.3. 
Species Clonal Strain Year Source Penner Donor 
Complex first 
isolated 
C. jejuni ST22 3752 1991 Human 19 M. Maiden 
C.jejuni ST42 3744 1991 Human 23 M. Maiden 
C. jejuni ST45 409266 1999 Human 57 M. Maiden 
C.jejuni ST49 3060 1991 Human 18 M. Maiden 
C. jejuni ST61 450964 1998 Beef Ofal 50 M. Maiden 
C. jejuni ST177 79196 1994 Sand NT M. Maiden 
C. jejuni ST206 2666 1991 Human NT M. Maiden 
C. jejuni ST362 C649/94 1994 Human 41 M. Maiden 
C. jejuni ST43 NCTC 1977 Human 2 T. 
11168 Humphries 
C. jejuni ST267 NCTC 1981 Human - T. 
81116 Humphries 
C. co/i NCTC 1980 Pig 4 T. 
11366 Humphries 
C. lari NCTC 1980 Herring - T. 
11352 Gull Humphries 
Table 2.2 Table of Campylobacter spp. used throughout this project. Dr M. Maiden - Dept. 
of Zoology, University of Cambridge. Prof. T. Humphries - University of Bristol 
Species Strain Genotype Source 
E. co/i TGI G. Reid 
E. co/i BL21(DE3) F- ompT hsdSB(rB- mB-) gal M. Gallagher 
dcm (DE3) 
E. co/i Tuner TM F- ompT hsdSB (nB- mB-) gal Novagen 
(DE3) dcm lacYl (DE3) 
Table 2.3 Table of E. coil strains used in cloning experiments. Prof. G. Reid - University of 
Edinburgh. Dr. M. Gallagher - University of Edinburgh 
W. 
2.2.3 Myeloma cell lines 
The myeloma cell lines used in this work are detailed in Table 2.4. 
Cell line 	Description 	 Source 
P3-X63-Ag8 	Derived from the P3X27 cell line, itself a derivative A. Merdes 
of mineral oil-induced plasmacytoma MOPC-21 in 
BALBIc mice. Resistant to 20pg/ml azaguanine, 
does not grow in selective medium. HGPRT neg. 
dies in HAT. Doubling time 16-26 h. 
Sp210'-Ag14 Sp2/0-Ag14 is a non-Ig-secreting or synthesising 	J. Ross 
line derived from a cell line created by fusing a 
BALB/c mouse spleen cell and the mouse 
myeloma P3X63Ag8. Resistant to 8-azaguanine at 
20ug/mI and does not survive in HAT containing 
media. 	 -- 
Table 2.4 Myeloma cell lines used in hybridoma experiments, a short description of the 
cell line and their source. Dr A Merdes - University of Edinburgh. Dr J Ross - University 
of Edinburgh. 
2.2.4 Stock solutions 
All stock solutions were stored at room temperature and sterilised at 121 °C for 
20 min unless otherwise stated. Where more than one grade of reagent was available, 
the highest quality was always used. 
2.2.4.1 0.2 M Calcium chloride 
A solution of 43.8 g CaC126H 20 in 800 ml distilled water was prepared. Once 
the components were dissolved completely the volume was adjusted to 1 1 before 
sterilisation. 
2.2.4.2 0.5 M EDTA 
A solution of 186.12 g disodium ethylenediaminetetraacetate (Na 2EDTA) in 
800 ml distilled water was prepared. The pH of the media was adjusted to 8.0 using 
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NaOH pellets and then accurately adjusted to 8.0 using 10 M NaOH. The final volume 
of the medium was adjusted to 11 before sterilisation. 
2.2.4.3 1 M Tris 
A solution of 121.14 g tris(hydroxymethyl)aminomethane (Tris) in 800 ml 
distilled water was prepared. The pH of the solution was adjusted to 7.4, 7.6 or 8.0 
using concentrated HC1. The final volume was adjusted to 11 with distilled water before 
sterilisation. 
2.2.4.4 20% (w/v) SOS 
A solution of 200 g sodium dodecyl sulphate crystals (SDS) in 900 ml distilled 
water was prepared. The solution was heated, with stirring, until all the crystals had 
dissolved. Once the components were dissolved completely, the p1-I was adjusted to 7.2 
with HC1 and the final volume adjusted to 11 with distilled water. This solution was not 
sterilised. 
2.2.4.5 0.1 M IPTG 
A solution of 1.19 g isopropyl -D-thiogalactopyranoside (IPTG) in 40 ml 
distilled water was prepared. Once the components were dissolved completely the final 
volume was adjusted to 50 ml and filter sterilised with a 0.22 gm filter. Aliquots (1 ml) 
were made and stored at -20 °C until needed; working stocks were stored at 5 °C in the 
dark for a maximum of 2 weeks. 
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2.2.4.6 X-gal (20 mgml 1 ) 
A solution of 400 mg 5-bromo-4-chloro-3-indoyl-3-D-galactoside (X-gal) in 
20 ml N,N'-dimethyl formamide was prepared. Aliquots were made and stored at 
-20 °C protected from light; working stocks were stored at 5 °C in the dark for a 
maximum of 2 weeks. This solution was not sterilised. 
2.2.4.7 lOx PBS 
A solution of 80 gNaCl, 2 g KC1, 26.8 g Na2HP04 7H2O and 2.4 g KH2PO 4 in 
800 ml distilled water was prepared. The pH of the solution was then adjusted to 7.4 
using HCl and then the final volume adjusted to 11 with distilled water. 
2.2.4.8 TE 
To make TE solution, 10 ml 1 M Tris (see 2.2.4.3) at the appropriate pH and 
2 ml 0.5 M EDTA (see 2.2.4.2) was added to 800 ml distilled water. Once mixed 
thoroughly, the volume was adjusted to 11 using distilled water before sterilisation. 
2.2.4.9 0.2 M Sodium phosphate, mono-sodium salt 
A solution of 27.6 g NaH2PO4 +120 in 500 ml distilled water was prepared. Once 
dissolved the final volume was adjusted to 11 with distilled water before sterilisation. 
2.2.4.10 	0.2 M Sodium phosphate, di-sodium salt 
A solution of 53.62 g Na 2HP04 7H2O in 500 ml distilled water was prepared. 




2.2.4.11 	0.1 M Sodium phosphate 
To make 0.1 M sodium phosphate of a specific pH, 0.1 M sodium phosphate 
mono sodium salt (see 2.2.4.9) and 0.2 M sodium phosphate di-sodium salt (see 
2.2.4.10) was mixed according to the Table in appendix A to obtain a 200 ml solution of 
0.1 M sodium phosphate with a specific pH. 
2.2.4.12 	lOx agarose gel sample buffer 
A solution of 250 mg bromophenol blue and 250 mg xylene cyanol in 33 ml 
150 mM Tris pH 7.6 (see 2.2.4.3) was prepared. Once dissolved, 60 ml sterile glycerol 
and 7 ml distilled water were added. This solution was not sterilised. 
2.2.4.13 	1 O TBE 
A solution of 108 g Tris and 55 g Boric acid in 900 ml distilled water was 
prepared. Once dissolved, 40 ml 0.5 M EDTA pH 8.0 (see 2.2.4.2) was added. The pH 
was checked and adjusted to 8.0. The final volume was then brought up to 1 1 with 
distilled water. 
2.2.4.14 	Ethidium Bromide 
A solution of 1 g ethidium bromide in 100 ml distilled water was prepared. The 
solution was not sterilised and stored at room temperature in the dark. 
2.2.4.15 	lOx SOS PAGE running buffer 
A solution of 10 g SDS, 30.3 g Tris and 144.1 g glycine in 800 ml distilled water 
was prepared. Once dissolved, the final volume was adjusted to 11 with distilled water. 
This solution was not sterilised. 
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2.2.4.16 	2x SDS PAGE sample buffer 
To make 2x SIDS PAGE buffer, 10 ml 1.5 M Tris pH 6.8 was mixed with 6 ml 
20% (w/v) SIDS (see 2.2.4.4), 30 ml glycerol and 15 ml 13-mercaptoethanol. Once mixed 
thoroughly, 3.6 mg bromophenol blue was dissolved in the mixture and the final volume 
adjusted to 100 ml. The solution was divided into aliquots (5 ml) and stored at -20 °C. 
This solution was not sterilised. 
2.2.4.17 	Coomassie Blue staining solution 
A solution of 2.5 g 'Coomassie Brilliant Blue R-250' in a mixture of 450 ml 
methanol, 100 ml acetic acid and 400 ml distilled water was prepared. The final volume 
was then adjusted to 1 1 with distilled water and filter through Whatman No. 1 filter 
paper before use. This solution was not sterilised. 
2.2.4.18 	Coomassie Blue destaining solution 
To make Coomassie blue destaining solution, 450 ml methanol, 100 ml acetic 
acid and 400 ml distilled water were mixed. Once mixed thoroughly, the final volume 
was adjusted to 11 with distilled water. This solution was not sterilised. 
2.2.4.19 	1000x Ampicillin 
A solution of 1 g ampicillin (amp) in 10 ml distilled water was prepared. Once 
dissolved, the solution was sterilised with a 0.22 p.m filter and stored at -20 °C. 
2.2.4.20 	1000x Chioramphenicol 
A solution of 3.5 g chioramphenicol (cmr) in 10 ml absolute ethanol was 





A solution of 10 g Bacto-Tryptone, 5 g Bacto-Yeast extract and 10 g NaCl in 
900 ml distilled water was prepared. The pH of the solution was adjusted to 7.0 with 
10 M NaOH and the volume adjusted to 11 with distilled water before sterilisation. 
2.2.4.22 	soc 
A solution 20 g Bacto-Tryptone, 5 g Bacto-Yeast extract, 0.5 g NaCl, and 2.5 ml 
1 M KCI was mixed with 900 ml distilled water. The p1-I was adjusted to 7.0 with 10 M 
NaOH and the volume adjusted to 990 ml with distilled water sterilisation. Before use 
10 ml sterile 1 M MgCl2 and 20 ml of 1 M glucose were added. After addition of MgCl 2 
and glucose the SOC was stored at 5 °C. 
2.2.4.23 	Brucella broth 
To make Brucella broth, 28 g dehydrated brucella broth was added to 11 distilled 
water. The broth was heated with stirring until completely dissolved. 
2.2.4.24 	Denaturing lysis buffer 
A solution of 13.8 g NaH2PO4H20, 1.2 g Tris and 480.5 g urea in 600 ml 
distilled water was prepared. Once dissolved, the pH was adjusted to 8.0 with NaOH 
and the fmal volume to 1 1 with distilled water. This buffer was not sterilised. Before 
use the pH of the buffer was checked and readjusted as necessary. 
2.2.4.25 	Wash buffer 
Composition of wash buffer is identical to denaturing lysis buffer (see 2.2.4.24). 
Immediately before use the pH of an appropriate amount of denaturing lysis buffer was 
adjusted to 6.3. 
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2.2.4.26 	Elution buffer A 
Composition of elution buffer A is identical to denaturing lysis buffer (see 
2.2.4.24). Immediately before use the pH of an appropriate amount of denaturing lysis 
buffer was adjusted to 5.9. 
2.2.4.27 	Elution buffer B 
Composition of elution buffer B is identical to denaturing lysis buffer (see 
2.2.4.24). Immediately before use the pH of an appropriate amount of denaturing lysis 
buffer was adjusted to 4.5. 
2.2.4.28 	ELISA coating buffer 
A solution of 794 mg Na2CO3 , 1.47 g NaHCO3 in 800 ml of distilled water was 
prepared. Once the components were dissolved completely, 100 tl 0.01 % (w/v) NaN3 
was added; the pH adjusted to 9.5 with NaOH and the final volume brought up to 11 
with distilled water. This buffer was not sterilised. 
2.2.4.29 	0.1 M Citric acid 
A solution of 19.2 g citric acid in 1 1 of distilled water was prepared; filter 
sterilised with a 0.22 pm filter and stored at 5 °C in the dark. 
2.2.4.30 	ELISA substrate buffer 
Substrate buffer was made immediately before use by mixing 6 ml 0.1 M citric 
acid (see 2.2.4.29), 6.4 ml 0.2 Na 21-1PO4 (see 2.2.4.10), 12.5 ml distilled water and 
dissolving 20 mg 0-phenylenediamine in the mixture. Once the components were 
dissolved completely and mixed, 10 p1 30% (wlv) H202 was added. This solution was 
not sterilised. 
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2.2.5 Tissue culture related media and stock solutions 
All tissue culture media was filter sterilised (0.22 tm filter) or obtained sterile 
from the supplier (Gibco, unless otherwise indicated) and tissue culture grade. All 
subsequent mixing of media was carried out in a Class II air flow cabinet. 
2.2.5.1 Freund's complete adjuvant 
Freund's complete adjuvant (FCA) is a suspension of either Mycobacterium 
tuberculosis or M butryicum in a mixture of paraffin oil and mannide monooleate. 
Before injection FCA is mixed with the antigen to form a water-oil emulsion. 
2.2.5.2 Freund's incomplete adjuvant 
Freund's incomplete adjuvant (FIA) has the same composition as FCA (see 
2.2.5.1 ) but does not contain any Mycobacterium spp. 
2.2.5.3 100 mM sodium pyruvate 
A solution of 550 mg sodium pyruvate (Sigma) in 50 ml distilled water was 
prepared. After sterilisation sodium pyruvate was stored at 5 °C. 
2.2.5.4 Myeloma culture media 
To 500 ml of RPMI-1640 with glutamine, 50 ml foetal bovine serum (USDA 
Approved), 10 ml 200 mM glutamine, 5 ml Pen-strep, 3 ml lOOx non-essential amino 
acids and 5 ml 100 mM sodium pyruvate (see 2.2.5.3) was added. The complete 
myeloma culture media (MCM) was stored at 5 °C. 
2.2.5.5 Serum free medium 
To 500 ml of RPMI-1640 with glutamine, 10 ml 200 mM glutamine, 5 ml 
Pen-strep, 3 ml lOOx non-essential amino acids and 5 ml 100 mM sodium pyruvate (see 
2.2.5.3) was added. The serum free media (SFM) was stored at 5 °C. 
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2.2.5.6 Complete hybridoma medium 
To 500 ml of RPMI- 1640 with glutamine, 50 ml foetal bovine serum (Fusion 
tested, USDA Approved), 10 ml 200 mM glutamine, 5 ml Pen-strep, 3 ml 
bOx non-essential amino acids, 5 ml 100 mM sodium pyruvate (see 2.2.5.3) and 50 ml 
PH-Comdimed (Roche). The complete hybridoma medium (CHM) was stored at 5 °C. 
2.2.5.7 HAT medium 
To make hypoxyanthine-aminopterin-thymidine medium (HAT), one vial each of 
HT Hybri-Max (Sigma) and aminopterin Hybri-Max (Sigma) were added to 500 ml 
CI-IM (see 2.2.5.6) according to manufacturer's instructions. HAT was stored at 5 °C. 
2.2.5.8 HT medium 
One vial of HT Hybrid-Max (Sigma) was added to 500 ml of CHM (see 2.2.5.6) 
according to the manufacturer's instructions. I-IT was stored at 5 °C. 
2.3 Growth of bacterial species 
2.3.1 Growth of Campylobacterspp. 
Campylobacter spp. cultures were incubated at 42 °C in Brucella broth for 48 h 
under micro-aerophilic conditions in gas jars (5% 02,  10% CO2 , 80% N2 (BOC)). When 




Vancomycin 5 mg 
Trimethoprim 2.5 mg 
Polymixin B 1250 IU 
Distilled water 2 ml 
Table 2.5 Composition of 250x Skirrow antibiotics. IU= inhibitory units 
2.3.2 Growth of E. coil strains 
All E. co/i strains were grown at 37 °C in LB (see 2.2.4.21) or on LB-agar. 
Broth cultures were grown in a vessel approximately five times the size of the culture 
volume and shaken at 200 rpm for the duration of the incubation. Where necessary 
antibiotics were added from the 1000x stock solutions (LB-amp, LB-cmr or 
LB-amp-cmr) (see 2.2.4.19 and 2.2.4.20). 
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2.4 DNA Purification 
2.4.1 Genomic DNA purification 
Genomic DNA was isolated using either the Wizard Genomic Kit (Promega) or 
the AquaPure Genomic Kit (BioRad). In both cases the manufacturers' instructions 
were followed except that 10 ml of Campylobacter spp. was substituted for I ml of E. 
co/i culture. 
2.4.2 Plasmid purification 
Plasmids were purified from 1 ml of overnight culture using the Wizard 
Miniprep kit (Promega). 
2.4.3 Gel purification of PCR products and plasmids 
After electrophoresis (see 2.5.1) the band of interest was excised from the 
agarose gel using a clean scalpel. DNA was then extracted from the gel using the 
QiAquick Gel Extraction Kit (Qiagen). 
2.4.4 Purification of PCR products 
PCR products were purified using the QlAquick PCR purification kit (Qiagen) 
and long template PCR (LT-PCR) products were purified using the Chargeswitch PCR 
purification kit (Invitrogen). 
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2.5 DNA detection and analysis 
2.5.1 Electrophoresis of DNA 
All agarose gels were made by weighing an appropriate amount of 
electrophoresis grade agarose (Invitrogen) and dissolving, using a microwave oven, in 
100 ml 0.5x TBE (see 2.2.4.13). Once the agarose had cooled slightly the solution was 
poured into a gel tray, a 16 well comb attached and the gel allowed to set. DNA samples 
were prepared by adding 5 .tl agarose gel loading buffer (see 2.2.4.12) into the sample. 
Either a 100 bp or 1 kb (NEB) DNA ladder was loaded at either side of the gel as 
appropriate for the size of bands expected. A maximum of 30 p.1 of sample was then 
loaded in the intermediate lanes. All gels were run in 0•5x  TBE (see 2.2.4.13) and at 
100 V. Once complete the gels were stained with ethidium bromide as described in 
2.5.3. 
2.5.2 Pulsed Field Gel Electrophoresis of LT-PCR products 
PFGE gels was made by dissolving 1.2 g of PFGE certified agarose (BioRad) in 
120 ml Ø.5x  TBE (see 2.2.4.13), using a microwave oven. After allowing the solution to 
cool slightly the gel was poured into the casting tray, a 20 well comb attached and the 
gel allowed to set. While the gel was setting 2 1 0.5x  TBE (see 2.2.4.13) was put into 
the PFGE tank and cooled to 14.0 °C. 
PCR products were purified as described in 2.4.4, then 5 p.d agarose gel loading 
buffer was added to 50 p.1 purified PCR product. Care was taken to mix the sample 
carefully to prevent undue DNA shearing. Mono-cut PFGE marker (1 p.g) (NEB) was 
loaded at either side of the gel and the samples loaded in the intermediate lanes. Gels 
were run with the following conditions using the CHIEF-DR II PFGE system (BioRad): 
6 Vcm' 
Run time = 22 h 
• Switch times = 0.5 - 1.5 sec (linear gradient) 
Once the run was complete, gels were stained using ethidium bromide as 
described in 2.5.3. 
2.5.3 Staining of aga rose gels 
Stock ethidium bromide solution (100 gil) (see 2.2.4.14) was added to 500 ml 
distilled water. Gels were immersed in the solution for 15 min and photographed under 
UV light in an Epichem darkroom II (UVP). If destaining was required, gels were 
immersed in 500 ml distilled water for 15 min before photographing. 
2.5.4 Sequencing of DNA 
Sequencing reactions were set up as detailed in Table 2.7, using the BigDye 
sequencing kit (version 3. 1, Applied Biosystems). The sequencing reaction was carried 
out on a MBS 0.2 G thermal cycler and the cycling conditions used were: 
• 25 times 
o 3O sec at95°C 
o 2O sec at5O°C 
o 4 min ató0°C 
Completed reactions were made up to a final volume of 20 jtl with distilled water 
before analysis on an ABI 3730 genetic analyser (Applied Biosystems). The raw 
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sequence data was analysed using BioEdit (Department of Microbiology, North Carolina 
University) and aligned to known sequences using Vector NTI (version 10, Invitrogen). 
Component 	Amount 
Template DNA - 400 ng 
Primer 1.6 pmol 
BigDye Mix 4 p1 
Distilled water To 10 p1 
Table 2.6 Composition of sequencing reactions 
2.6 Protein detection and analysis 
2.6.1 SOS-PAGE 
Stock 30% (w/v) acrylamide (Severn Biotech Ltd) was mixed with separating 
(1.5 M Tris pH 8.8) and stacking (0.5 M Tris pH 6.8) gel buffers according to Table 2.8. 
The separating gel was mixed with 200 p.1 of 20% (w/v) ammonium persuiphate (made 
immediately before use) and 10 p.1 of TEMED. After pouring, the separating gel was 
covered with a layer of distilled water and left to polymerise at room temperature. Once 
the separating gel had polymerised, the stacking gel was mixed with 200 p.1 
20% (w/v) ammonium persuiphate and 10 p.1 TEMED. A 10 well comb was inserted 
into the stacking gel and the gel left to polymerise at room temperature. Before running 
the wells were washed with distilled water to remove any traces of unpolymerised 
actylamide. 
Protein samples were prepared by mixing with an equal volume of 2x SDS 
PAGE sample buffer (see 2.2.4.16) and incubated in a boiling water bath for 5 mm. The 
amount of each sample loaded was adjusted so that total protein amounts per lane were 
equal (see 2.6.5). The first well in all gels was loaded with 1 p.1 of the Broadrange 3 
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Protein ladder (NEB). Gels were run at 100 V until the dye front had run the length of 
the gel. 
Amount (ml) 
Final% 4 	12.5 
Component 
Acrylamide 30% 4 	10 
Separating gel buffer - 	 6 
Stacking gel buffer 6 - 
Distilled water 14 	8 
Table 2.7 Composition of the Stacking (4% wlv) and separating (12.5% w/v) 
polyacrylamide gels used for electrophoresis of proteins. 
2.6.2 Coomassie blue staining of SOS-PAGE gels 
Gels were incubated with 100 ml of Coomassie blue staining solution 
(see 2.2.4.17) at room temperature for 15 - 20 mm. After incubation the staining 
solution was removed and the gel incubated with Coomassie blue destaining solution 
until bands were visible. Destained gels were photographed backlit with white light and 
a Epichem II darkroom. 
2.6.3 Gelcode blue staining of SDS-PAGE gels 
Gels were fixed in 50 ml 5% (v/v) methanol and 7% (v/v) acetic acid for 15 mm. 
After fixing, the gels were washed with 50 ml distilled water. The distilled water was 
discarded after 5 min and the gel covered in Gelcode blue (Perkin-Elmer). The gel was 
incubated at room temperature for 30 min to 1 h with shaking. Gels were destained with 
100 ml distilled water overnight before photographing as a Coomassie stained gel 
(see 2.6.2). 
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2.6.4 Determination of total protein concentration 
Total protein concentration was determined using the BioRad protein assay kit 
with bovine serum albumin (NEB) as a standard. 
2.6.5 Equalisation of loading amounts 
When it was not possible to directly measure total protein, the amount of sample 
to be loaded was determined by the following formula: 
Volume to load (p.!) = ____ 270 
1 6.6xA600nm 
2.7 Amplified fragment length polymorphism (AFLP) analysis of 
Campylobacter spp. 
2.7.1 Digestion of genomic DNA and ligation of adaptors 
Approximately, 400 ng of purified genomic DNA (see 2.4. 1) was incubated with 
10 U EcoRI (NEB), 3 U T4 DNA ligase (Promega) and 50 pmol each adaptor strand 
(see Table 2.1). The reaction was carried out at 37 °C for 1 h. The restriction/ligation 
mix was made using the supplied 1 Ox ligase reaction buffer and the final volume of the 
reaction was 50 p.1. 
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2.7.2 Amplification of ligated fragments 
Amplification reactions were set up according to Table 2.8 and carried out either 
in a MBS 0.2 G thermal cycler (ThermoElectron) or a Progene thermal cycler (Techne). 
The cycling conditions used were: 
5 min at94°C 
. 30 times 
o 30 sec at94°C 
o 30 sec at 55.5 °C 
o l min at72°C 
5 min at72°C 
Once cycling was complete the reaction was run on a 2.5% (w/v) agarose gel at 
100V for 120 mm. 
Component Amount 
Restriction/ligation reaction 5 p1 
Primer 100 pmol 
Taq DNA polymerase 1 U 
lOx Taq DNA polymerase buffer 5 p1 
dNTPs 1 mM 1 p1 
Distilled water To 50 p1 
Table 2.8 Composition of EcoRl-AFLP amplification reactions. 
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2.7.3 Amplification of AFLP controls 
Each control was amplified in separate reactions from purified C. jejuni NCTC 
11168 genomic DNA. The PCR reactions were set up according to Table 2.10 and 
carried out in a MBS 0.2 G thermal cycler. The cycling conditions used were: 
5 min at94°C 
. 30 times 
o 30 sec at94°C 
o 3O sec at50°C 
a l min at72°C 
10 mm at 72 °C 
Component Amount 
Template DNA 100 ng 
lOx Fwd primer 5 p1 
lOx Rev primer 5 p1 
Taq DNA polymerase 0.5 p1 
lOx Taq DNA polymerase buffer 5 p1 
dNTPs 1 mM 1 	p1 
Distilled water To 50 p1 
Table 2.9 Composition of PCR reactions for amplification of each AFLP control from 
genomic DNA. 
2.8 CPS-RFLP of C. jejuni 
2.8.1 Amplification of single genes from the CPS locus 
Primers for the kps genes, cj1430, hddC and gmhA2 (see Table 2.1) were 
designed based the genomic sequences of C. jejuni NCTC 11168, RM 1221 and the 
published CPS loci sequences of Penner serotypes HS:23/36 and HS:41, using Vector 
NTI (version 10, Invitrogen). Individual PCR reactions were set up according Table 
2.10 and amplification was carried out in a MBS 0.2 G thermal cycler 
(ThermoElectron). The following cycling conditions were used: 
5 min at94°C 
. 30 times 
o 3O sec at94°C 
o 3O sec at55°C 
o 60 sec at72°C 
5 min at72°C 
Component Amount 
Template DNA —100 ng 
Working stock forward primer 5 p1 
Working stock reverse primer 5 p1 
Taq DNA polymerase 0.5 p1 
1 Ox Taq DNA polymerase buffer 5 p1 
dNTPs 1 mM 1 p1 
Distilled water To 50 p1 
Table 2.10 Composition of PCR reactions used to amplify single genes from the CPS 
Icous of C. jejuni 
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2.8.2 Long template PCR of the C. jejun! CPS locus 
An aliquot of 1 ml from a two day old culture, was spun at - 16 000 g for five 
minutes in a microcentrifuge. The supernatant was discarded and the pellet was 
resuspended in 10 j.iI of distilled water. Before the reactions were set up, the lOx 
ExpandTM DNA polymerase buffer was heated to 42 °C for 2 h. Reactions were set up 
according to Table 2.11 using the ExpandTM 20 kb plus kit (Roche) and amplification 
carried out in a MIBS 0.2 G thermal cycler (ThermoElectron). The following cycling 
conditions were used: 
• 5 min at94°C 
• 10 times 
o 3O sec at94°C 
o 3O sec at5O°C 
o l0minat64°C 
• 20 times 
o 3O sec at94°C 
o 30 sec at50°C 
o 10 mm at 64 °C plus 20 sec per cycle 
• l0 min at64°C 
M. 
Component Amount 
Resuspended cells 2 p1 
Working stock gmhA2Fwd 2.4 p1 
Working stock KpsD-SRev2 2.4 p1 
Expand TM DNA polymerase mix 1 p1 
lOx Expandm DNA polymerase buffer 5 p1 
dNTPs 1 mM 2.5 p1 
Distilled water To 50 p1 
Table 2.11 Compositon of the long template PCR reactions used to amplify the section of 
the C. jejuni CPS locus from gmhA2 to KpsS using the Expand(tm) 20 kb plus kit (Roche). 
2.8.3 RFLP of long template PCR products 
After purification as in 2.4.4, long template PCR products were digested with either 
EcoRl, Bcll, BglII or NdeI. All reactions were carried out at 37 °C for 1 h and setup 
according to Table 2.12. 
Component Amount 
Purified LT-PCR product 20 p1 
Restriction enzyme 1 	pP 
Restriction enzyme buffer 5 pP 
BSA (10 mg/ml) 1 	p1 
Distilled water To 30 pP 
Table 2.12 Composition of the restriction digest reaction used for CPS-RFLP. 
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2.9 Construction of His-tagged PEB3 
2.9.1 Cloning of peb3 
Primers for peb3 (see Table 2.1) were designed based on the published sequence 
of C. jejuni NCTC 11168 using VectorNTl (version 10, Invitrogen). PCR reactions 
were set up according to Table 2.14 and amplification was carried out in a MBS 0.2 G 
thermal cycler (ThermoElectron). The following cycling conditions were used: 
. S min at94°C 
. 30 times 
o 3O sec at94°C 
o 30 sec at 55.5 °C 
o 6O sec at72°C 
• 5 min at72°C 
Component Amount 
Template DNA —100 ng 
Working stock PEB3Fwd 5 p1 
Working stock PEB3Rev 5 p1 
Taq DNA polymerase 0.5 p1 
1 O Taq DNA polymerase buffer 5 p1 
dNTPs 1 mM 1 p1 
Distilled water To 50 p1 
Table 2.13 Composition of the peb3 amplification reactions 
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2.9.2 Preparation of chemically competent E. coil 
LB (5 ml) (see 2.2.4.2 1) was inoculated with the appropriate strain of E. co/i and 
incubated overnight at 37 °C with shaking at 200 rpm. LB (5 ml) was then inoculated 
with 200 1.11 overnight culture and incubated at 37 °C with shaking at 200 rpm until the 
A600nm 0.8. All 5 ml of the culture was spun at 3 500 g in a microcentrifuge at 5 °C 
for 2 mm. The supernatant was discarded and the cells were re-suspended in 2 ml ice 
cold 0.2 M CaCl2 (see 2.2.4.1). The cells were incubated for I h on ice and then spun 
at 3 500 g in a microcentrifuge at 5 °C for 2 mm. The supernatant was discarded and 
the cells were re-suspended in I ml ice cold 0.2 M CaCl2. The cells were then incubated 
on ice for at least 45 min before use. 
2.9.3 Ligation of insert into pGEM-T 
The plasmid pGEM-T is available ready-prepared with an optimised DNA ligase 
from Promega. The manufacturer's instructions were followed and the ligations carried 
out at 5 °C overnight to maximise the number of transformants. Once complete the 
ligation reaction was used to transform E. coli TG 1 cells (see 2.9.4). 
2.9.4 Transformation of competent E. coil 
An entire ligation reaction or 5 pi of purified plasmid preparation (see 2.4.2) 
were placed on ice with 200 p.1 of competent cells for 5 mm. The cells were then heat 
shocked by incubating at 42 °C in a water bath for 1 min 45 sec. The cells were then 
immediately placed on ice and 800 .tl of room temperature SOC (see 2.2.4.22) was 
added. The cells were then incubated at 37 °C for 30 min with shaking at 200 rpm. 
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2.9.5 Screening for pGEM-T clones 
LB-amp plates were dried and had 100 jil IPTG (see 2.2.4.5) and 20 pA X-Gal 
(see 2.2.4.6) added and spread thoroughly across the surface of the plates. After 
preparation of transformed cells (see 2.9.4), the cells were spun down at - 16 000 g in a 
microcentrifuge for 5 mm. The cells were resupended in 100 pA of supernatant and 
spread across the surface of a plate before being incubated at 37 °C overnight. Clones 
positive for insert appeared as white colonies and were subcultured onto LB-amp plates. 
Five positive colonies were also used to inoculate 5 ml of LB-amp and incubated at 
37 °C overnight with shaking at 200 rpm. 
Plasmid was purified from the overnight cultures (see 2.4.2) and sequentially 
digested with 2 000 U of NdeI (NEB) for 1 h at 37 °C and then 2 000 U of BamHl 
(NEB) for a further 1 h. Digestions were set up according to Table 2.15. Agarose gel 
sample buffer (5 pA) (see 2.2.4.12) was added to the digestion and 30 1.il run on a 1% 
(w/v) agarose gel (see 2.5). Plasmids that showed an insert equal to the size of the 
expected insert were then sequenced (see 2.5.4). This screen was repeated until a clone 
containing the correct insert was identified. 
Component Amount 
Purified plasmid 	 .._ 5 p1 
Ndel 2 000 U 
BamHl 2 000 U 
NEB restriction enzyme buffer 4 3 p1 
BSA lOpgpl 1 0.5 p1 
Distilled water To 30 p1 
Table 2.14 Composition of the digestion reaction for the screening of pGEM-T-PEB3 
clones. 
72 
2.9.6 Preparation of pET-16b vector 
Purified pET-i 6b (1 g) (Novagen) was digested sequentially with 2 000 U of 
NdeI for I h at 37 °C and 2 000 U of BamHI for a further hour. The digestions were set 
up according to Table 2.16. Upon completion of digestion 1 000 U calf intestinal 
phosphatase (NEB) was added to the restriction reaction and the reaction was incubated 
at 37 °C for 1 h. Agarose gel sample buffer (5 l.tl) (see 2.2.4.12) was added to the 
dephosphorylated plasmid and run on a 1% (w/v) agarose gel (see 2.5). The plasmid 
was then purified from the agarose (see 2.4.3) for use in ligation reactions. 
Component Amount 
Purified plasmid 5 p1 
NdeI 2 000 U 
BamHl 2 000 U 
NEB restriction enzyme buffer 4 3 p1 
BSA lOpgpI 1 0.5 p1 
Distilled water To 30 p1 
Table 2.15 Composition of restriction reactions for the preparation of the pET-I 6b vector 
2.9.7 Ligation of insert into pET-16b clones 
Insert from pGEM-T-PEB3 was gel purified (see 2.4.3) and ligated into purified 
pET-16b (see 2.9.6) according to Table 2.1. All ligation reactions were incubated 
overnight at 5 °C. Once complete, the ligation reaction was used to transform E. coil 
TG  cells (see 2.9.4). 
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Ratio (vector: insert) 
Component 2:1 1:1 1:2 1:3 
pET-16b 2 p1 1 p1 1 	p1 1 p1 
Insert I p1 1 p1 2 p1 3 p1 
14 DNA ligase 1 	p1 1 p1 1 p1 1 p1 
lOx T4 DNA ligase buffer 1 p1 1 p1 1 p1 1 p1 
Distilled water To 10 p1 To 10 p1 To 10 p1 To 10 p1 
Table 2.16 Composition of ligation reactions for the ligation of peb3 into pET-16b. 
2.9.8 Screening of pSAN3 transformants 
After incubation (see 2.9.4 and 2.9.7), pET-16b-PEB3 (renamed pSAN3) 
transformed cells were spun at 16 000 g in a microcentrifuge for 5 min re-suspended in 
100 tl of supernatant; then spread thoroughly across the surface of I LB-amp-cmr plate 
and incubated at 37 °C overnight. After incubation, colonies were subcultured onto LB-
amp-cmr plates and five colonies selected for screening. The screen was performed in 
the same way as for the pGEM-T-PEB3 screen (see 2.9.5). 
The plasmid from one positive clone was purified (see 2.4.2) and transformed 
into E. coil TunerTM cells (see 2.9.4). After incubation, transformed cells were spun 
down at - 16 000 g in a microcentrifuge and then re-suspended in 100 l of supernatant. 
The re-suspended cells were then spread on a LB-amp-cmr plate and the plates were 
incubated at 37 °C overnight. To screen for protein expression, five colonies were used 
to inoculate 5 ml of LB-amp-cmr and incubated overnight at 37 °C with shaking at 200 
rpm. From each overnight culture, 200 Ltl was used to inoculate 5 ml LB-amp-cmr, 
which was the incubated at 37 °C with shaking at 200 rpm until the A600nm 
Cultures were then induced with 0.1 mM IPTG (see 2.2.4.5) and incubated for 3 h at 
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37 °C with shaking at 200 rpm. An extra uninduced culture was set up as a negative 
induction control. After induction, I ml culture was harvested and the cell density 
measured at Aônm  and a I ml aliquot was spun down at - 16 000 g in a microcentrifuge 
and resupended in 15 p1 of distilled water and 15 .tl of SDS-PAGE sample buffer 
(see 2.2.4.16). 
The A600nm  of each culture was used to standardise the loading amounts for each 
culture (see 2.6.5). All samples were analysed by SDS-PAGE (see 2.6). This process 
was repeated until a clone over-expressing a protein at the expected Mr of the cloned 
protein was obtained. 
2.10 Expression of His.PEB3 
Fifty millilitres of LB-amp-cmr was inoculated with the pSAN3 clone and 
incubated overnight at 37 °C with shaking at 200 rpm. After incubation, the 50 ml 
overnight culture was split and used to inoculate 3x  11 of LB-amp-cmr and incubated at 
37 °C with shaking at 200 rpm until the A600nm was 0.8. Once the A600 m  was reached 
the cultures were induced with 0.1 mlvi IPTG (see 2.2.4.5) for 3 h at 37 °C with shaking 
at 200 rpm. After induction, the cells were spun down at 10 000 g for 15 mm. 
2.11 Denaturing purification of His.PEB3 
Cell pellets from His.PEB3 inductions (see 2.10) were re-suspended in 25 ml of 
denaturing lysis buffer (see 2.2.4.24). The cells were lysed by mixing gently at room 
temperature for 60 mm. The lysate was then centrifuge at 10 000 g for 20 min to pellet 
cell debris. 
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The Ni-ATA agarose (Qiagen) was shaken well before use to ensure an even 
suspension and half a millilitre of agarose was added to a gravity flow column and 
allowed to settle. The agarose was equilibrated with 4 washes of 5 ml of denaturing 
lysis buffer. The cleared lysate was then added to the column and mixed with the 
agarose at room temperature for 60 mm. After mixing, the agarose was allowed to settle 
and drain. The column was then washed twice with 4 ml of wash buffer (see 2.2.4.25) 
and twice with 4m1 of elution buffer A (see 2.2.4.26). The purified protein was then 
eluted from the column in 2 ml of elution buffer B (see 2.2.4.27). The composition of 
the washes and elutents was analysed by SDS PAGE (see 2.6). 
2.12 Enzyme Linked Immunosorbent Assay (ELISA) 
Purified His.PEB3 (see 2.11) was diluted to a final concentration of 10 p.gm1 1 in 
ELISA coating buffer (see 2.2.4.28). One hundred microlitres of diluted protein was 
added to each well of a 96-well flat bottomed microtitre plate and incubated at 5 °C 
overnight. After incubation, the plate was washed in PBS + 0.05% (v/v) Tween 20 with 
a Dynex M.R.W. V 2 plate washer. The washing cycle was as follows: 
• 4 times 
o Remove liquid 
o Add 300 p.1 wash solution 
After washing, any residual liquid was removed by inversion and tapping of the 
plate on paper towel. The plate was then blocked using 200 p.1 of 1% (wlv) skimmed 
milk in coating buffer per well and incubating at 37 °C for 1 h in a humidified incubator. 
During blocking primary antibody dilutions were prepared in 0.25% (w/v) skimmed 
we 
milk PBS + 0.05% (v/v) Tween 20. After blocking, plates were washed as above and 
residual wash solution removed. One hundred microlitres of each antibody dilution was 
then added to the appropriate wells on the plate and incubated at room temperature for 4 
h. After incubation, the plate was washed as above and any residual buffer removed. 
Secondary antibody was diluted in 0.25% (w/v) skimmed milk PBS + 0.05% 
(v/v) Tween 20 according to the manufacture's instructions. One hundred microlitres of 
diluted secondary antibody was added to each well of the plate and incubated at 37 °C 
for 30 mm. After incubation, the plate was washed and any residual buffer removed as 
above. 
One hundred microlitres of freshly prepared substrate buffer (see 2.2.4.30) was 
added to each well and the plate incubated at room temperature for 15 mm. The reaction 
was stopped by the addition of 50 j.tl of I M H2SO4  and the A492nm  of each well read in a 
Ronsys anthos 2010 plate reader. 
2.12.1 ELISA end point titre determination 
End point titres were calculated according to the equation: 
End point titre = Mean of 6 Secondary antibody controls + 0.2 OD units 
(Kemeny, 1991) 
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2.13 Production of monoclonal antibodies 
2.13.1 Challenge of BALB/C mice with His.PEB3 
Two separate challenges were carried out according to Table 2.18 and Table 
2.19. In both cases antigen was prepared by mixing an equal volume of antigen and 
adjuvant through a 19 gauge needle until a thick emulsion was formed. Once an 
emulsion was formed, it was injected subcutaneously into each animal. All animal work 
for these challenges was carried out by National Diagnostics (Scottish National Blood 
Transfusion Service, Bush, Scotland). 
Procedure Day Antigen amount (pg) Adjuvant Date 
Preimmune bleed 0 26/05/04 
Challenge 1 0 15 FCA 26/05/04 
Challenge 2 28 15 FIA 23/06/04 
Challenge 3 56 15 FIA 21/07/04 
Test bleed 61 -... -.._-__- 28/07/04 
Challenge 4 96 15 FIA 1/10/04 
Exsanguination and 99 4/10/04 
Splenctomy 
Table 2.17 Schedule A used to challenge two BALB/C mice with 15 pg of His.PE133 for the 
production of monoclonal antibodies. 
Procedure Day Antigen amount (ig) Adjuvant Date 
Preimmune bleed 0 10/01/05 
Challenge 1 0 100 FCA 10/01/05 
Challenge 2 28 100 FIA 7/02/05 
Test Bleed 35 14/02/05 
Challenge 3 42 100 FIA 21/02/05 
Exsangiunation and 46 25/02/05 
Splenctomy 
Table 2.18 Schedule B used to challenge two BALBIC mice with 100 pg of His.PE133 for 
the production of monoclonal antibodies. 
2.13.2 Preparation of serum 
Serum was prepared by allowing bleeds to clot at 4 °C overnight and then 
centrifugation at 10 000 rpm in a microcentrifuge for 2 mm. Serum was then extracted 
taking care to not to disturb the clot. If any red blood cells were present in the serum, it 
was re-spun at 10 000 rpm in a microcentrifuge for 2 min to pellet the cells before 
decanting into another tube. Serum was stored at -20 °C until use. 
2.13.3 Growth of myeloma cells 
A vial of cells (see 2.2.3) was removed from liquid nitrogen storage and rapidly 
defrosted at 37 °C. The cells were then washed 3 times in 30 ml of SFM (see 2.2.5.5) 
and harvested by centrifugation at 2 000 rpm for 5 mm. After the final wash the cell 
pellet was re-suspended in 10 ml of MCM (see 2.2.5.4), placed in a 55 cm2 tissue culture 
Petri dish and incubated at 37 °C under 5% CO2 for two days in a humidified incubator. 
After incubation, spent media was replaced by an equal volume of fresh media every 2 d 
until the cells reached a density of 1 —5 x 105  cell m1 1 . 
The cells were then harvested by gentle washing with the spent media until all 
cells had detached from the surface of the dish. If necessary, cells were detached by 
washing with 5 ml of PBS (see 2.2.4.7) and then incubating with 1 ml of trypsin-EDTA 
for 10 min at 37 °C. The suspension was then divided equally between 3 dishes and 
fresh MCM used to bring the final volume to 10 ml. This process was repeated so that 
cell density reached but never exceeded I - 5 x 105 cells m1' until the cells were needed. 
On the day of fusion, 1 x 108  cells were harvested and washed in 30 ml SFM. 
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2.13.4 Harvest of splenocytes 
The spleen was placed into a Petri dish on top of a square of sterile gauze and 10 
ml SFM (see 2.2.5.5) added. The sterile gauze was folded over the spleen several times 
to create a pouch. A cell scraper was then used to burst the spleen and squeeze out the 
splenocytes until only the tough spleen capsule remained. Splenocytes were washed out 
the gauze using the SFM in the Petri dish. The suspension of SFM and splenocytes was 
removed and placed to one side. The Petri dish and gauze were then thoroughly washed 
with SFM to ensure all splenocytes were harvested. The cells were then pelleted at 1 
000 rpm for 1 min in a benchtop centrifuge. The supernatant was removed and the cells 
washed in 30 ml fresh SFM and pelleted as above. The cells were washed a further 4 
times in 30 ml SFM. 
2.13.5 Fusion of myelomas and splenocytes 
Washed splenocytes (see 2.13.4) and washed myelomas (see 2.13.3) were 
combined in one tube and washed twice in 30 ml SFM (see 2.2.5.5). After washing, the 
tube was flicked to ensure an even mixture of cells within the pellet. Over the course of 
30 sec, I ml PEG 1500 (Roche) was added to the pellet with gentle flicking; the tube 
was flicked gently for a further I min 30 sec. Fresh SFM (5m1) was added over the 
course of 30 sec; from approximately 8" above the pellet, without flicking. A further 5 
ml SFM was added over 30 sec with flicking; before the addition of a final 10 ml SFM. 
The cells were harvested by centrifugation at 1 000 rpm for 1 min and then re-
suspended in 10 ml fresh SFM. The suspension was then placed in a Petri dish and 
incubated at 37 °C under 5% CO2 in a humidified incubator for 30 mm. After 
incubation, the cells were removed from the dish and the dish washed with SFM. The 
HE 
cells were harvested by centrifugation at 1 000 rpm for 1 min and then re-suspended in 
30 ml CHM (see 2.2.5.6). The suspension was pipetted into 96 well tissue culture plates 
(100 tl per well) and then incubated for 1 day at 37 °C under 5% CO2 in a humidified 
incubator. 
2.13.6 Selection and screening of hybriodmas 
Fused cells (see 2.13.5) were subjected to FIAT selection one day after fusion. 
Fused cells were fed with 200 p.1 2x FIAT (see 2.2.5.7) per well. The plates were then 
incubated for 2 days at 37 °C under 5% CO2 in a humidified incubator. Cells were fed 
by removing 100 p.1 of media from each well and replacing it with 100 p.1 of fresh HAT 
before incubating as before. After 3 feedings, the cells were then fed with HT 
(see 2.2.5.8) instead of HAT. This process was then repeated until all wells of a plate 
tested negative for Anti-His.PEB3 production (see 2.12). 
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2.14 Production of polyclonal antibodies 
2.14.1 Challenge of New Zealand White rabbits 
Three New Zealand white rabbits were challenged with 0.95 mg of His.PEB3 per 
injection according to the schedule in Table 2.20 (Harlan Sera-lab, Hillcrest, UK). 
Serum was prepared as in 2.13.2 and tested for the presence of Anti-His.PE133 (see 
2.12). 
Procedure Day Antigen Amount (pg) Adjuvant Date 
Preimmune 0 25/07/05 
bleed 
Challenge 1 0 950 FCA 25/07/05 
Challenge 2 14 950 FIA 8/08/05 
Challenge 3 28 950 FIA 22/08/05 
Test Bleed 1 35 29/08/05 
Challenge 4 42 950 FIA 5/09/05 
Test Bleed 2 49 12/09/05 
Challenge 5 56 950 FIA 19/09/05 
Test Bleed 3 63 26/09/05 
Challenge 6 70 950 FIA 3/10/05 
Exsanguination 77 10/10/05 
Table 2.19 Schedule for the challenge of 3 New Zealand white rabbits, against His.PEB3 
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Results and Discussion - Typing systems 
3.1 Introduction to typing systems currently in use 
Epidemiological analysis relies on the use of typing systems. Without the 
power to discriminate between different isolates, it would be impossible to determine 
the relationship between separate outbreaks. Unlike Salmonella and E. coli, cases of 
C. jejuni are sporadic; often with considerable time periods between cases. 
Determining commonality between seemingly unrelated cases is therefore only 
possible by accurate identification of isolates. 
A wide variety of typing systems have been developed for use with C. jejuni 
(see 1.6). The majority of these rely on DNA based comparisons to distinguish 
between strains e.g. 16S rRNA, tla-RFLP, PFGE, AFLP and MLST. DNA-DNA 
based comparisons are highly sensitive as often single base pair differences can 
influence the result. This however presents its own problems as most rely on PCR to 
amplify sequences for comparison. A sequence that is both stable and conserved 
across strains is required for primer binding. 
The most popular typing scheme currently in use is Penner serotyping. This 
scheme uses antibodies against CPS to agglutinate sensitised erythrocytes in the 
presence of each C. jejuni serotype. The level of discriminatory power that this 
achieves is low when compared to the DNA based techniques. Analysis of the 
sequenced genome (C. jejuni NCTC 11168) shows that the CPS is probably phase 
variable, which could cause variable serotyping results for each isolate. Despite this 
Penner serotyping has remained widely used. The Penner scheme has survived as the 
primary typing scheme because it requires minimal technical skill when compared to 
DNA based techniques. It is also relatively difficult to translate results from one 
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scheme to another, making comparison to pre-DNA-era isolates difficult. 
AFLP has been widely studied and used to type large numbers of C .jejuni 
isolates. Briefly, whole genomic DNA is subjected to restriction digest. Restriction 
site specific adaptors are then ligated to the restriction fragments. Primers specific 
for the adaptor sequences are then used to amplify the fragments within a specified 
size range (commonly 50 - 500 bp). The amplified fragments are then size separated 
and visualised. The technique has changed little since its first publication (Vos et al., 
1995), despite it being stated that the technique would require optimisation for each 
organism it is used with. 
In this chapter an attempt to optimise the AFLP technique for use with 
C. jejuni is described. In addition a novel technique based on PCR-RFLP, that will 
allow straightforward comparison to Penner serotyping is also described. 
3.2 Optimisation of AFLP 
3.2.1 Using in silico analysis of the published C.jejuni NCTC 11168 
genome to predict AFLP profiles 
Previous attempts to improve the AFLP typing scheme have been based upon 
trial and error of different restriction enzymes. It was decided to use the published 
genomic DNA sequence and in silico analysis to select restriction enzymes for 
practical analysis. 
The selection of restriction enzymes for in silico analysis was made using 
three criteria: A. the enzyme must cut at the restriction site B. the enzyme must 
produce an overhang on restriction and C. the cost of the enzyme should not prevent 
routine use (defined as any enzyme costing < £ 20 per 50 U). Fourteen enzymes 
were selected for analysis (see Table 3.1). The published sequence of C. jejuni 
NCTC 11168 (Parkhill et al., 2000) was analysed using two programs, the 
Comprehensive microbial resource (TIGR) and a custom built program (Needham, 
unpublished 2002). Results for each enzyme singly and in combination were 
produced from both programs simultaneously and compared. Differences were only 
observed in the position used for the start of each fragment but this had no effect on 
the calculated sizes as it was consistent throughout all calculations. Once all the data 
was collated the number of fragments within the range 50 - 500 bp was calculated, as 













Table 3.1 Restriction enzymes and their recognition sites picked for use in prediction 
of C. jejuni NCTC 11168 AFLP profiles (the position of the cut in the restriction site is 
indicated by Y) 
Enzyme 	Affil Apal 	BamHl Bc/i EcoRl Hpall Kpnl MIul PstI Xbal 
At/it 	50 22 30 149 92 73 25 28 79 61 
Apal 0 	1 71 29 29 1 3 33 14 
BamHI 1 84 41 41 6 6 36 23 
Bc/i 71 162 146 84 100 153 135 
EcoRl 29 85 34 56 82 74 
Hpatl 29 32 39 87 73 
KpnI 1 5 39 23 
MIul 3 51 28 
Pstl 33 66 
Xbal 14 
Table 3.2 Predicted number of fragments within the range 50 - 500 bp produced by the 
in silico restriction of C. jejuni NCTC 11168 by stated enzyme combinations. 
The optimal restriction enzyme combination is dependent on the method used 
to visualise the AFLP profiles. Visualisation methods can be split into two groups 
based upon the amount of DNA needed for detection. High sensitivity techniques 
such as radio-labelling or fluorescently labelled primers require fg of DNA per 
fragment for detection; whereas low sensitivity techniques such as SYBR Green or 
EtBr staining require ng of DNA per fragment for detection. Of significance when 
determining the optimum restriction enzyme combination, different separation 
matrices are used for each sensitivity group. High sensitivity techniques use 
polyacrylamide or polyacrylamide mixes and usually longer gel lengths are utilised 
with than low sensitivity techniques. This means that fragments with 1 bp 
differences in size can be resolved but the size ranges that can be analysed are 
smaller and less flexible. Most fluorescent-primer detection methods rely on the use 
of automated sequencers for separation of fragments. In theory such machines 
should be able to resolve 450 fragments in the 50 - 500 bp range (assuming there is a 
fragment for each size). However, limits in signal separation mean this is rarely 
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achieved. The practical detection limit is approximately 300 fragments, depending 
on the conditions used. Low sensitivity techniques generally use agarose as the 
separation matrix. In comparison to polyacrylamide, a 15 cm long agarose gel has a 
theoretical detection limit of 30 bands. Therefore, enzyme combinations suitable for 
a high sensitivity technique will not necessarily be useable in low sensitivity 
techniques. 
The optimum restriction enzyme combination can therefore be defined as: 
the enzyme combination that produces enough bands to allow the use of statistical 
techniques in distinguishing strains and fewer bands than the theoretical resolution 
limit of the detection method.' 
Using the definition of the optimum enzyme combination all of the enzyme 
combinations in Table 3.2 could be used for AFLP analysis of C. jejuni. To 
determine which of these best fulfils the discrimination criteria for the optimal 
combination, practical comparison of AFLP profiles from a set of strains is needed. 
It was decided to use EcoRI initially as these had successfully used with C. jejuni 
previously (Arnold et al., 1999), as well as HpaII and XbaI. Additionally primers 
and adaptors were designed for use with XbaI. In all cases single digests were 
predicted to produce profiles that are suitable for EtBr visualisation and double 
digests suitable for fluorescent analysis. 
3.2.2 In vitro AFLP analysis of C. jej uni NCTC 11168 genomic DNA 
The AFLP procedure was first described by Vos et al. in 1995. A slight 
modification was made (Peters and Threlfall, 2001) to change the system into a 
single restriction enzyme technique. Initial experiments with EcoRl were not 
successful, as they did not provide any visible bands after staining with EtBr. The 
procedure was then further modified to take into account the sensitivity difference 
between EtBr staining and fluorescent detection. After modification the reactions 
produced a ladder-like profile with bands at 30 bp and then every 30 bp thereafter. 
This is probably due to the formation of primer/adaptor dimers during the 
amplification. A series of dilutions of primers and adaptors was prepared to 
minimise dimer formation but had no effect. 
Both primers and adaptors were re-synthesised and used in parallel with older 
oligos. When the re-synthesised oligos were used no ladder-like profile was seen, 
this suggests that the adaptor EcoRIAdapi had been incorrectly synthesised 
preventing ligation of the adaptor to the restriction fragments. A gradient PCR was 
then used to maximise the number of bands seen (see Figure 3.1). The profile was 
then compared to the expected profile obtained from in silico analysis. Not all the 
expected bands were observed and all of the observed bands were sized to within 2 - 
3 bp of expected bands (see Figure 3.2). 
AFLP reactions were also performed with HpaII and XbaI at the same time 
using the same conditions as the EcoRI reactions. With all enzymes the profiles 
obtained were consistent for 4 - 5 reactions but then became less distinct and less 
reproducible, particularly within the size range 50 - 500 bp. Bands observed in the 










Annealing temperature (°C) 
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Figure 3.1 2.5 % (w/v) agarose gel showing the EcoRl AFLP profile of C. jejuni NCTC 
11168 and the effect of annealing temperature on the AFLP profile. Whole genomic 
DNA (400 ng) from C. jejuni NCTC 11168 was digested with EcoRl. Adaptors specific 
to the restriction site were then ligated to the restriction fragments before 
amplification with primers specific to the adaptor sequence. Each represents a 
different annealing temperature (stated at the top of each lane) used during 
amplification. As the annealing temperature increases the number of fragments 



















y = -79.025Ln(x) + 628.37 
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Figure 3.2 Comparison of expected fragments to observed fragments for the EcoRl 
AFLP profile of C. jejuni NCTC 11168. Known fragment sizes were used to calculate a 
standard curve (A). The equation for the standard curve (y= -79.0251n(x) + 628.37) was 
used to position the expected fragments against the photograph (B). Arrows indicate 
the position of corresponding bands between expected and observed. 
A series of control fragments were designed to investigate possible variables 
in the AFLP protocol. Using the in silico analysis, primers were designed that would 
amplify four of the expected EcoRl fragments. AFLP reactions with each control 
fragment separately and in combination were performed. The control fragments 
showed that restriction and ligation were not affected by size as all fragments 
appeared when processed separately (see Figure 3.3). However, control fragment 1 
(153 bp) was never observed when processed in combination with other fragments. 
Control fragment 2 (255 bp) was not observed when processed with control fragment 
4 (555 bp) but was present in all other combinations. Both control fragments 3 
(306 bp) and 4 were observed in all combinations. Control fragment 4 was always 
present in greater abundance than any other fragment. These results show clearly 
that larger fragments were preferentially amplified. It would be expected that 
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fragment size would influence amplification efficiency as a natural bias towards 







Figure 3.3 2.5 % (w/v) agarose gel showing the amplification of each EcoRl AFLP 
control after being processed using the AFLP protocol. Each control fragment was 
amplified from C. jejuni NCTC 11168 genomic DNA and then digested with EcoRl. 
Adaptors specific to the EcoRl restriction site were ligated to each fragment and 
primers specific to the adaptors used to amplify each fragment. Lane 1: Control 
fragment 1 (153 bp) Lane 2: Control fragment 2 (255 bp) Lane 3: Control fragment 3 
(306 bp) Lane 4: Control fragment 4 (555 bp) 
The efficiency of any PCR reaction is dependent on a number of factors: 
template quality, template amount, primer concentration, dNTP concentration, Mg 2+  
concentration, KC1 concentration and enzyme amount. For most PCR reactions little 
or no optimisation is required. However, in more complex PCR protocols such as 
multiplex PCR, extensive optimisation of each variable may be required. It was 
decided to use troubleshooting techniques for multiplex PCR on the AFLP protocol 
as the two processes are similar in nature. 
Using reactions combining control fragments 2 and 4, the effect of each factor 
(see above), BSA addition (to stabilise enzyme) and decrease in reaction volume, 
was investigated. Reducing reaction volume, adding BSA, doubling dNTP or 
increasing the primer concentration, all caused the yield to increase (- 2 fold) (see 
Figure 3.4). A 4 fold increase in the amount of enzyme added per reaction gave an 
increased yield of 10 fold (see Figure 3.4). Changing both Mg 2 and KCI 
concentration caused the amplifications to fail. In all cases where an increase in 
yield was observed, control fragment 4 was amplified preferentially to control 
fragment 2. 
The %GC value is known to affect the efficiency of long template PCR (see 
3.3.1), to test the effect of %GC on AFLP reactions, both X (%GC = 50 (Monocut 
DNA ladder, NEB)) and W. succinogens (%GC = 48.5) were processed with both 
EcoRI and HpaII protocols. No effect due to %GC was apparent (see Figure 3.5). 
The standard AFLP protocol does not include any steps for removing 
restriction fragments not of interest i.e. those above 500 bp in size. To investigate 
the effect of the ratio of total fragments to fragments of interest, enzymes which 
produced fragments with ends compatible with EcoRI and HpaII were used. The two 
additional enzymes MfeI (EcoRl compatible) and BstBI (HpaII compatible) had 
ratios of 16:1 and 9:1 repectively c.f. EcoRl 10:1 and HpaIl 7:1. X DNA (as above), 
W. succinogens and C. jejuni NCTC 11168 genomic DNA were processed with all 
four enzymes but no effect due to the ratio of total fragments to fragments of interest 
was apparent (see Figure 3.6). 
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1 	2 	3 	4 	5 	6 	7 
Control 4 
Control 2 
Figure 3.4 2.5 % (w/v) agarose gel showing the effects of changing reaction conditions 
on the amplification of EcoRl AFLP control fragments 2 and 4. Lane 1: Control 
reaction. The yield is approximately twice the control when the reaction volume is 
halved (2), BSA is added to a final concentration of 0.8 pgpr 1 (3), doubling dNTP 
concentration (5) and increasing primer concentration (6 and 7). Increasing the 
amount of enzyme 4 fold in the reaction caused the yield to increase -10 fold (4). In all 
cases control fragment 4 was amplified preferentially to control fragment 2. 
A W C 
Figure 3.5 1 % (wlv) agarose gel showing that %GC does not affect the Hpall AFLP 
profile for Lambda Mono-cut ladder (50 %) (NEB) (A), W. succinogens DMSZ 1740 
(48.5%) (W) and C. jejuni NCTC 11168 (30.6 %) (C). Genomic DNA (400 ng) was 
digested with HpaIl and Hpall restriction site specific adaptors ligated to the 
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Enzyme Species Ratio 
EcoRl A 11:0 
W 11.9:1 
C 10:1 
Mfel A 14:1 
W 21:1 
C 16:1 
Hpall A 1.8:1 
W 5.5:1 
C 7:1 
BstBl A 13:0 
W 12.5:1 
C 9:1 
Figure 3.6 1 % (w/v) agarose gel (A) showing the AFLP profiles for Lambda Mono-cut 
DNA (NEB) (A), W. succinogens DMSZ 1740 (W) and C. jejuni NCTC 11168 (C). 
Genomic DNA (400 ng) from each species was digested in separate reactions with 
EcoRl, Mfel, Hpall and BstBl. Adaptors specific to the EcoRl restriction site were 
ligated to EcoRl and Mfel fragments. Adaptors specific to the HpalI restriction site 
were ligated to Hpall and BstBI fragments. Adaptor specific primers were then used 
to amplify each fragment set. The ratio, total fragments:fragments in range 50 - 500 
bp, was determined to see if this affected the success of the AFLP profile. The ratios 
are shown in B. 
The original AFLP protocol uses two rounds of amplification before 
visualisation. The first, non-selective amplification to increase the total amount of 
template DNA in the range 50 - 500 bp and the second selective amplification to 
amplify a subset of fragments within the 50 - 500 bp range. The selective 
amplification uses a primer modified by the addition of between I and 3 extra 
nucleotides at the 3' end. Selective EcoRI primers (EcoRIPr+A and EcoRIPr+C) 
were used to amplify C. jejuni NCTC 11168 EcoRI fragments after a round of non-
selective amplification. In both cases no previously unobserved bands were obtained 
(data not shown). 
3.2.3 AFLP repeatability is sensitive to a wide variety of factors both 
biological and technical 
The experiments performed above show that the success of an individual 
AFLP reaction is: 
. Independent of the substrate genomic DNA used 
Independent of the primers used 
Independent of the adaptors used 
The variability of the AFLP reactions (even when performed in parallel) must 
therefore be introduced by processing differences between each individual sample. 
Any small differences are then magnified by the amplification step of the AFLP 
protocol. A known problem of porting PCR protocols between thermal cyclers is 
variation in the thermal profiles of different blocks, meaning a small amount of 
optimisation is often required to achieve equivalent results. 
A key requisite of any typing system is portability and reproducibility 
between laboratories. The CAMPYNET project was an EU funded project to 
standardise typing protocols for C. jejuni and C. co/i. While standardised protocols 
forfla-RFLP and PFGE were achieved (Harrington et al., 2003), it proved impossible 
to standardise AFLP. It was concluded that differences in "separation and detection 
apparatus" prevented comparison of AFLP patterns produced by different 
laboratories and methods (http://campynet.vetinst.dklnews.htm ). 
3.3 The CPS locus is potentially a good target for RFLP analysis of C. 
jejuni 
RFLP compares restriction pattern differences in single genes or loci between 
strains. Initially, RFLP was performed by restriction of whole genomic DNA, 
electrophoresis, Southern blotting and probing for a specific gene of interest. The 
advent of PCR led to a modification of the RFLP protocol where the target is 
amplified before restriction and the pattern visualised directly. The main advantage 
of PCR-RFLP is its speed when compared to RFLP. 
A number of typing schemes utilising different restriction enzymes and 
primers against flaA and flaB in C. jejuni are currently in use (Harrington et at., 
2003). Other targets used include, 16S rRNA, 23S rRNA (Moreno et at., 2002), 
groEL (Karenlampi et at., 2004) and hipO (Slater et at., 1997). 
The discriminatory power of PCR-RFLP varies depending on the specific 
target, but is generally higher than Penner serotyping (60 serotypes) and lower than 
AFLP or MLST (658 sequence types). One means of increasing discriminatory 
power is to increase the number of target genes. Two locus based schemes have been 
proposed using the wia gene cluster (Misawa et at., 2001) and the LOS locus (Nakari 
et at., 2005). The use of the LOS locus was also an attempt to harmonise Penner 
serotyping with DNA based typing systems. Although a working scheme was 
produced, harmonisation was not achieved. 
It has been shown that the serodeterminate of Penner serotyping is CPS 
(Karlyshev et at., 2000). Described below is an attempt to create a PCR-RFLP 
typing scheme that uses the CPS locus as a target and harmonises Penner serotyping 
with RFLP. 
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The conserved structure of the CPS locus makes it a good choice for RFLP 
analysis. All of the sequenced loci conform to the Gram negative group II capsule 
locus structure (see Figure 3.7 and Figure 3.8); with transport genes flanking a 
variable region of sugar transferases. To investigate the degree of conservation 
within the kps genes (responsible for transport), primers based upon the C. jejuni 
NCTC 11168 sequences, were designed for kpsM, E, D, F and S. Each gene was 
amplified and sequenced from isolates with the following Penner serotypes (HS): 18, 
23, 50 and 57. In all of the genes the sequenced sections (-j 66% of the total gene 
length) had between 90 % and 100 % identity (alignments for kpsD and kpsS are 
shown in appendix B). Primers for the conserved sequences in kpsD and kpsS were 
designed for amplification of the CPS locus. Because of the extreme length of the 
locus it was necessary to use long template (LT) PCR (see 3.3.1). 
Salmonella group B 
V 	 — -- 
'.L 
Ia,r.JIr1IfI!JJJ 'J.! 
E. coil K12(016) 
E. coil dysenteriae  
(type 1) 
Plasmid pHW400 	 chromosome 
Figure 3.7 Schematic of the CPS locus in two serotype groups of Salmonella and two strains of E. coil. Each colour represents a 
separate branch of the CPS biosynthetic pathway. With the exception of E. coil dysenteriae (typel) all loci are chromosomally 
encoded. 
----------------------------- 
kpsS kpsC 	 kpsF kpsDkpsE kpsT kpsM 
hddCgmhA2 cj1430 
Figure 3.8 Schematic of the known CPS loci types in C. jejuni. Type I loci (top) follow the Gram negative Group Il CPS locus structure 
with the kps genes flanking a variable region of sugar transferases. Type II loci (bottom) follow the same structure, but with have 
three conserved genes within the conserved region, hddC, gmhA2, and cj1430. 
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3.3.1 Long template PCR- using polymerase mixtures to amplify large 
(>10 kb) sequences of DNA 
Standard PCR techniques utilising Taq polymerase (or other non-
proofreading polymerases) have maximum amplicon lengths of - 5 kb. This 
limitation is caused by the incorporation of incorrect bases during amplification. 
When such a mismatch occurs, the polymerase stalls and is unable to continue 
replication. Proofreading enzymes, such as Pfu, do not stall on the incorporation of 
mismatched bases as they possess exonuclease activity and can remove the incorrect 
base. However, the exonuclease activity lowers the processivity of the enzyme 
making amplification of long sequences time consuming. In both cases the thermal 
stability of the polymerase is important in determining maximum amplicon length 
(Huang et al., 1992). 
One method of increasing the maximum amplicon length is to use a mixture 
of non-proofreading and proofreading enzyme in the amplification mixture. In such 
a mixture the non-proofreading enzyme provides the processivity to decrease 
amplification time and the proofreading enzyme to allow extension of incomplete 
product when mismatches occur (see Figure 3.9). Enzyme stability is increased by 
changes in the reaction buffer (see Table 3.3 for comparison) and using a lower 
extension temperature to lower thermal degradation. This technique was patented by 
Roche and two kits are available for the amplification of sequences up to —28 kb in 
size. The maximum amplicon size is dependent on the target sequence; the largest 
sequences amplified from ? genomic DNA are 40 kb compared to 25 kb from human 
genomic DNA. The exact reason for this is unknown but has been theorised to be 
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Figure 3.9 Schematic of the processes occurring during the amplification step of a 
Long template PCR reaction. 1. Taq polymerase (circle) extends the primer until a 
mismatch occurs (red circle). 2. The Taq polymerase stalls and unbinds from the DNA 
strands. 3. Pfu polymerase then binds and removes the mismatch and continues 
extension. 4. Extension is then completed by either polymerase. 
3.3.2 Purification of PCR products> 10 kb 
Amplification of long sequences presents problems during purification after 
PCR. It is desirable to purify the products before restriction digest because of the 
high salt content in the PCR buffer, which may inhibit restriction. Most commonly, 
removal of salt us achieved by EtOH/isopropanol precipitation or using silica and 
Nal (e.g. QlAquick PCR clean up kit (Qiagen)). Both methods have disadvantages; 
EtOH precipitation is not always efficient at removing salt from the DNA and silica 
will irreversibly bind DNA above 10 kb in size. Both methods were compared using 
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the Mono-cut ladder (NEB) in LT-PCR reaction buffer (data not shown). As 
expected no DNA was recovered when silica was used. Two protocols for EtOH 
precipitation were compared, 30 min at -70 °C and overnight at -20 °C. Purification 
at -20 °C was -50 % efficient and no salt was co-precipitated. Purification at -70 °C 
was 90 % efficient but there was significant co-precipitation of salt. 
In 2005, Invitrogen introduced a new range of DNA purification products that 
uses a new technology called ChargeswitchTM. The purification system is based on 
using changes in pH to influence the charge of the ChargeswitchTM material. At low 
pH, ChargeswitchTM is positively charged and binds nucleic acids (see Figure 3.10). 
A wash step at neutral pH removes any contaminants or loosely bound material. The 
nucleic acid is then eluted by raising the pH with Tris.Cl pH 8.0 causing the 
ChargeswitchTM to lose charge. In practice, paramagnetic beads are coated with 
ChargeswitchTM to facilitate separation of the DNA at each step. When compared to 
EtOH precipitation, efficiency was >90 % and there was no co-purification of salt. 
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Figure 3.10 Schematic of the ChargeswitchTm purification system. DNA is 
electrostatically bound by mixing with ChargeswitchTm coated paramagnetic beads in 
an acidic solution. Loosly bound material and contaminants are then washed off with 
a pH neutral solution. DNA is eluted by adding and mildly alkaline solution, causing 
the ChargeswitchTM to lose charge and release the DNA. 
3.3.3 Sequence comparison of the known CPS loci to determine likely 
targets for primer binding 
An attempt to amplify the entire CPS locus (-40 kb) from C. jejuni NCTC 
11168 was made but failed. It was therefore necessary to design primers that binded 
within the variable region of the CPS locus (see Figure 3.8). The CPS loci of six 
Penner serotypes, HS:1, HS:19, HS:41, HS:23/36 (HS:23 and HS:36 have identical 
loci) and RM 1221 (serotype unknown) have been sequenced (Fouts et al., 2005, 
Karylshev et al., 2005 and Parkhill et al., 2000). Comparison of the sequenced loci 
showed that two subgroups of locus structure exist. The first group is identical to the 
Gram negative group II capsule locus structure. The second group consists of loci 
with a small island of partially conserved genes within the variable region of the 
locus and the locus size is —2 fold that of the first group. The conserved genes within 
this island are hddC, gmhA2 and cj1430. Primers for cj1430 and gmhA21hddC (the 
primer gmhA2Rev binds internally to hddC) were designed and used to detect their 
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presence in 10 C. jejuni strains. GrnhA2 was detected in 8 strains and cj1430 in 5 
strains (see Figure 3.11). To amplify cj1430 in the strain set, it was necessary to 
lower the annealing temperature used by 5 °C; suggesting that the sequence 
similarity at the primer binding sites is low. It was decided therefore, to use gin hA 2 
as an internal priming site. 
11168 













Figure 3.11 1 % (w/v) agarose gel showing the presence of gmhA2 and cj1430 in set of 
10 C.jejunistrains. GmhA2 (A) was detected in 8 strains and cj1430(B) in 5 strains. 
3.3.4 Amplification of the C. jejuni NCTC 11168 locus using multiple 
PCR reactions 
As previously stated (see 3.3.1) the maximum possible amplicon length is 
sequence dependent. Using the primers designed against the internal conserved 
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genes (see 3.3.3), LT-PCR reactions with differing combinations of primers were 
setup to determine the maximum possible amplicon length. Each of the reactions 
was successful with amplicons up to and including 25.9 kb amplified (see Figure 
3.12). During the course of these experiments the LT-PCR kit was modified by the 
manufacturer, with a change in the amount of proofreading enzyme and working 
Mg 2+  concentration. This change caused the amplification to cease working until the 
extension temperature was lowered to 64 °C to counteract the increased exonuclease 
activity. This caused a decrease in the maximum amplicon length and a decrease in 
amplification yield. Subsequently, amplification of products longer than 14 kb was 
not achieved. 
Figure 3.12 (Following page) Schematic showing the approximate binding sites of the 
primers used to amplify sections of the C. jejuni CPS locus. Each product is shown 
amplified after running on a I % (wlv) PFGE gel under the following conditions: 6 Vcm 
j,  0.5 - 1.5 $ linear ramped switch time for 22 h, the A Mono-cut DNA ladder included 
on each gel for reference. A: gmhA2-kpsD 25.3 kb B: kpsS-gmhA2 14.0 kb C: hddC-
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3.3.5 In silico analysis of the sequenced CPS loci to determine 
appropriate restriction enzymes for experimentation 
The expected amplification product from all sequenced CPS loci, using the 
primer pair kpsD-SRev2 and gmbA2Fwd, was generated using VectorNTl (version 
10, Invitrogen). The LT-PCR products were then digested in silico using NEBcutter 
(NEB), limiting output to enzymes available commercially and with fewer than 15 
restriction sites. The size distribution of the restriction fragments for each enzyme 
was then analysed and enzymes that produced fragments spaced across the size range 
1 - 10 kb selected. The restriction profiles for each strain were then compared and 
enzymes that could not distinguish each strain were discarded. The enzymes BclI, 
BglII, EcoRI and NdeI were selected for initial experimentation. The generated 



















Figure 3.13 Schematics showing the theoretical restriction patterns, as would be seen 
on a I % (w/v) agarose gel, for digests of the LT-PCR product KpsS-gmhA2 from 4 C. 
jejuni strains with the stated restriction enzymes. 1: NCTC 11168 (HS2) 2: HS23/36 3: 
HS4I 4: RM1221 (HS unknown) 
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3.3.6 CPS-RFLP of C.jejuni 
Digests were initially performed on the LT-PCR product produced from C. 
jejuni NCTC 11168, to ensure the accuracy of the in silico prediction allow 
optimisation of the restriction reaction. All the expected fragments were observed 
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Figure 3.14 1 % (w/v) agarose gel showing the restriction profiles for the LT-PCR 
product KpsS-gmhA2 from C. jejuni NCTC 11168 and a schematic showing the 
theoretical restriction profile. 1: EcoRl 2: 8cR 3: BgRl 4: Ndel. Products of incomplete 
digestion are shown by white arrows. 
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3.3.7 LT-PCR is unsuitable for use as a typing system 
Amplifications of the CPS loci in the reference strain set failed. This was 
unexpected as: 1. the primers had been used to amplify individual genes previously 
(see 3.3.3) and 2. the primers were designed based upon sequences obtained from 
the reference strain. Of the strains tested, only ST362's entire CPS locus is 
sequenced (HS:41). When compared to the locus from NCTC 11168 there is little 
(apart from gene complement) to distinguish it. In particular the known problems of 
%GC should be the same for both strains; as the %GC of each locus is almost 
identical (27 % and 26 %). 
There are significant differences between the buffers used for LT-PCR and 
normal PCR (see Table 3.3). The substitution of tricine for tris stabilises the buffer 
pH more effectively at high temperatures, in turn increasing DNA stability. The 
addition of glycerol serves to increase the thermal stability of the polymerases as well 
as lowering the effective melting temperatures of the DNA complexes. Of most 
importance is the addition of DMSO, the increase in Mg 2 and the substitution of 
KC1 for KOAc. DMSO lowers the effective melting temperature of the DNA strands 
(-5 °C for each 10 % v/v DMSO added) but lowers the thermal stability of the 
polymerases. The increase in Mg2 is to balance the required increase in dNTP 
concentration and maximise polymerase efficiency. The substitution of KC1 for 
KOAc, lowers the ionic strength of the buffer. In high %GC sequences this is 
thought to help destabilise any 2° structures that may form (Cheng, 1996). 
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Normal PCR LT-PCR 
10 mM tris (pH 8.3) 20 mM tricine (pH 8.7) 
None 10 % (w/v) glycerol 
None 2%(v/v)DMSO 
1.5mM M902 1.1 mM Mg(OAc)2 
50 mM KCI 80 mM KOAc 
Table 3.3 Buffer compositions use in normal PCR with Taq DNA polymerase and the 
LT-PCR Expand 20 kb plus kit from Roche. Detailed information regarding the 
composition of the buffer in LT-PCR is unknown as it is proprietry. The buffer 
composition presented in the table was taken from US patent 5512462 which covers 
the LT-PCR process. 
Experimentally the most noticeable effect was the lowering of melting 
temperatures. To amplify any part of the C. jejuni NCTC 11168 CPS locus it was 
necessary to lower the annealing temperature of the PCR reaction by 5 °C to 50 °C. 
It is possible that the buffer, designed to achieve maximum efficiency with high 
%GC templates, is destabilising the target DNA and primers too much. Thereby 
preventing annealing of primers to the template or partially completed amplicons to 
the template and consequently lowering the efficiency of amplification. 
At this time and with the ExpandTM 20kb plus LT-PCR kit, CPS-RFLP as 
described above is impossible. The theoretical comparisons of the CPS loci show 
them to be good targets for RFLP possessing both conserved priming sites (see 3.3.3) 
and enough variable material for identification (see 3.3.5). Investigation of other LT 
systems is therefore needed before CPS-RFLP is dismissed. 
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3.4 Conclusions 
• Small variations in sample processing can cause large variations in the AFLP 
profile observed. 
• The emergent technology of LT-PCR is currently too unreliable for typing 
use. 
• Sequence comparison of the known CPS loci, shows the potential for 
development of a DNA-DNA based typing scheme with the locus as a target. 
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Results and Discussion - Immunomagnetic separation 
4.1 Immunomagnetic separation 
Diagnostic laboratories can be presented with a wide variety of samples for 
investigation, e.g. faeces, food, swabs. Before the samples can be investigated, they 
must be processed so that the organisms of interest can be detected. The degree and 
type of processing is dependent on both the organism of interest and the final 
detection system. Traditionally, enrichment media was used to favour the growth of 
particular groups of organisms before separation into pure cultures and biochemical 
testing. A problem with such techniques is that the number of bacteria within an 
enrichment culture does not directly relate to the original number of bacteria within 
the sample. The traditional enrichment methods can take several days before testing 
can begin which is not ideal. 
As technology has progressed the use of PCR based detection techniques has 
become more common. In many cases detection of a target bacterium directly from a 
sample is possible. However, many of the samples will contain both compounds that 
interfere with the PCR reaction and other bacteria that may cross react. 
Immunomagnetic separation (IMS) provides a means both of enriching a target 
bacterium and removing it from contaminants. 
IMS works by mixing antibody coated paramagnetic beads with a sample and 
separation from the sample with a magnet (see Figure 4.1). Paramagnetic beads are 
used because they are only magnetic when a magnetic field is present, thus ensuring 
even mixing of the beads with the sample. The antibody which is attached to the 
beads is variable. Either an antibody recognising the target is directly conjugated to 
the beads or an anti-species antibody is conjugated to the beads; allowing the system 
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to be used against one or many targets. Other advantages of IMS over traditional 
enrichment techniques are: quick, technically simple, number of bacteria recovered 
relates directly to the number of bacteria within the original sample and recovered 
bacteria remain viable. Table 4.1 lists some of the bacteria that have been 















Figure 4.1 Schematic of the immunomagnetic separation procedure. 1: Antibody 
against the target bacterium is incubated with the contaminated sample. 2: Anti-
species coated paramagnetic beads are incubated with the contaminated sample to 
capture the bound target. 3: A magnetic field is applied and the contaminants 
removed. 4: Bound target is then washed and resuspended after removal of the 
magnetic field. Target can then be eluted from the beads if necessary. 
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Target 	 Sample 	 Detection method 	Reference 
E. co110157 	Faeces 	 Conventional culture 	Cubbon eta!, 1996 
Raw milk/Ice cream 	PCR 	 Gooding 	and 
Choudary, 1997 
Salmonella spp. 	Pork 	 Conventional culture 	Ripabelli et al., 1997 
sausages/chicken 	
Ripabelli et al., 1999 
meat/beef 
Listeria spp. 	Various 
	
Conventional culture 	Avoyne et al., 1997 
Salmonella 	and Various 
	
Conventional culture Karpiskova 	and 
Listeria spp. 	 Holasova, 1999 
Campy/obacter spp Various 	chicken Microtitre 	 Lamoureux et al., 
samples 	 hybridisation 	 1997 
Chicken and milk 	PCR 	 Docherty et al., 1996 
Table 4.1 Examples of bacteria that have been isolated using immunomagnetic 
separation, and the method used in their detection (Adapted from Clark, 2000) 
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4.2 Using the cell membrane protein PEB3 as a target for IMS 
4.2.1 Design of primers for the detection and cloning of peb3 
Primers for the amplification of peb3 were designed using the published 
sequence of C. jejuni NCTC 11168 (Parkhill et al., 2000). The primers included an 
NdeI or BamHJ recognition site to allow for use in directional cloning. The peb3 
sequence includes an N-terminal signal sequence with the predicted cleavage point 
between amino acid residue 20 and 21 (see Figure 4.2). 
S9noIP-MM pr•dtcton (gram- networks): S.qu.nc. 
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Figure 4.2 Graph of the signal sequence (S), Cleavage site (C) and a derivative of both 
scores (Y)for C. jejuni NCTC 11168 PEB3. A cleavage site is predicted where the 
slope of V is steep and Cis significant ( > 0.5). Cleavage site predicted using Signal-
P v 3.0 (Bendsten, Neilsen etal., 2004) 
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As the signal sequence would be cleaved in the mature protein the primer 
PEB3-FWD was redesigned so the first 20 amino acids would not be included in the 
cloned gene. 
4.2.2 Detection and comparison of peb3 in C. jejuni 
PCR was used to amplify peb3 in the C. jejuni reference strains. The results 
are shown in Figure 4.3. 






Figure 4.3 1 % (w/v) agarose gel showing the results of a PCR reaction using the 
primers PEB3-FWD and PEB3-REV on C. jejuni strains 1: NCTC 11168 2: NCTC 81116 
3: ST22 4: ST42 5: ST45 6: ST49 7: ST6I 8: ST177 9: ST206 10: ST 362 
The results show that peb3 is present in all of the reference C. jejuni strains. 
To determine the extent to which peb3 varies between the strains, sequencing of peb3 
in the strains NCTC 81116, ST22 and ST42 was carried out. The sequences were 
aligned to the sequence strain C. jejuni NCTC 11168 peb3 and no significant 
differences were found. 
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4.2.3 Directional cloning of peb3 
The peb3 gene was amplified as stated in 2.8.1. After amplification the PCR 
product was gel purified and ligated into pGEM-T EasyTM (Promega) as in 2.8.3. 
The ligation reaction was transformed into E. co/i TGI and screened using lacZ 
blue/white screening. Five of the positive clones were selected for further analysis 
(pGEM-TPEB3 1 to 35). The plasmid from each clone was purified and was checked 
for the presence of the insert using the primers PEB3-FWD and PEB3-REV. All of 
the clones tested positive for the insert in this way (data not shown). Each clone was 
then sequenced to check for base substitutions as Taq DNA polymerase was used in 
the initial construction of the insert (see Figure 4.4 for alignments). 
The sequencing results from pGEM-TPEB3 I showed several differences 
between the clone and the expected sequence. However, all of these mismatches are 
at the very beginning of each sequencing reaction and the corresponding bases on the 
complementary strand are identical to the expected sequence. Analysis of the peaks 
produced in the sequencing run shows that these mismatches are mostly caused by 
poor resolution of peaks at the beginning of each sequence (data not shown). pGEM-
TPEB3 I was selected as the source of the insert for creation of an expression clone. 
Sequential digestion of the purified plasmid with the restriction enzymes NdeI and 
BamHI was used to release the insert. The expression vector pET-16b (Novagen) 
was prepared by sequential digestion with NdeI and BamHI and dephosphorylation 
with calf intestinal phophatase to prevent recircularization. This vector was chosen 
because it enabled the addition of a His 10 tag. The His 10 tag was chosen as it does not 
affect the natural properties of the expressed protein significantly and allows easy 
purification. The gel-purified insert was ligated into the dephosphorylated pET-16b 
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vector as described in 2.8.7. Five clones (pSAN31-35) were screened for the 
presence of the insert by excision of the insert using NdeI and BamHl (data not 
shown) and the results were as predicted. The clone pSAN3 1 was selected for use 
and renamed pSAN3 (Figure 4.5). 
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1 36 
PCR product CAT ATG ACG GCC TTA AAA GAT ATA GCA AAC AAA TAT 
pGEM-TPEB31-FWD --- --- --- --- --- --- --- --- --- --- AAA TAT 
pGEM-TPEB31-REV CAT ATG ACG GCC TTA AAA GAT ATA GCA AAC AAA TAT 
37 85 
AGC GAA AAA ACA GGC GTT AAA GTA AAT GTA AAT TTT GGC CCT CAA GCG 
AGC IA AAA ACA GGC GTT AAJ CTA AAT GTA AAT TTT GGC CCT CAA GCG 
AGC GAA AAA ACA GGC GTT AAA GTA AAT GTA AAT TTT GGC CCT CAA GCG 
86 134 
ACT TGG TTT GAA AAG GCT AAA AAA GAT GCA GAT ATT TTA TTT GGC GCT 
ACT TGG TTT GAA AAG GCT AAA AAA GAT GCA GAT ATT TTA TTT GGC GCT 
ACT TGG TTT GAA AAG GCT AAA AAA GAT GCA GAT ATT TTA TTT GGC GCT 
135 183 
TCA GAT CAA TCG GCT TTA GCT ATA GCG AGT GAT TTT GGA AAA GAT TTT 
TCA GAT CAA TCG GCT TTA GCT ATA GCG AGT GAT TTT GGA AAA GAT TTT 
TCA GAT CAA TCG GCT TTA GCT ATA GCG AGT GAT TTT GGA AAA GAT TTT 
184 232 
AAT GTG AGT AAA ATC AAG CCT TTA TAT TTT AGA GAA GCC ATC ATA CTT 
AAT GTG AGT AAA ATC AAG CCT TTA TAT TTT AGA GAA GCC ATC ATA CTT 
AAT GTG AGT AAA ATC AAG CCT TTA TAT TTT AGA GAA GCC ATC ATA CTT 
233 281 
ACT CAA AAA GGC AAT CCT TTA AAA ATC AAA GGT TTA AAA GAT TTG GCT 
ACT CAA AAA GGC AAT CCT TTA AAA ATC AAA GGT TTA AAA GAT TTG GCT 
ACT CAA AAA GGC AAT CCT TTA AAA ATC AAA GGT TTA AAA GAT TTG GCT 
282 330 
AAT AAA AAA GTA AGA ATC GTT GTG CCT GAA GGT GCT GGA AAG AGC AAT 
AAT AAA AAA GTA AGA ATC GTT GTG CCT GAA GGT GCT GGA AAG AGC AAT 
AAT AAA AAA GTA AGA ATC GTT GTG CCT GAA GGT GCT GGA AAG AGC AAT 
Figure 4.4 Sequence alignment of pGEM-TPEB3I with the expected PEB3 clone 
sequence. Mismatches are highlighted in blue. 
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331 	 379 
ACT TCT GGA ACT GGA GTT TGG GAA GAT ATG ATA GGT AGA ACT CAA GAT 
ACT TCT GGA ACT GGA GTT TGG GAA GAT ATG ATA GGT AGA ACT CAA GAT 
ACT TCT GGA ACT GGA GTT TGG GAA GAT ATG ATA GGT AGA ACT CAA GAT 
380 	 428 
ATA AAA ACC ATA CAA AAT TTT AGA AAC AAT ATC GTG GCC TTT GTT CCA 
ATA AAA ACC ATA CAA AAT TTT AGA AAC AAT ATC GTG GCC TTT GTT CCA 
ATA AAA ACC ATA CAA AAT TTT AGA AAC AAT ATC GTG GCC TTT GTT CCA 
429 	 477 
AAT AGT GGA AGT GCA AGA AAG CTT TTC GCA CAA GAT CAA GCC GAT GCT 
AAT AGT GGA AGT GCA AGA AAG CTT TTC GCA CAA GAT CAA GCC GAT GCT 
AAT AGT GGA AGT GCA AGA AAG CTT TTC GCA CAA GAT CAA GCC GAT GCT 
478 	 526 
TGG ATC ACT TGG ATT GAC TGG TCA AAA AGC AAT CCT GAC ATA GGA ACT 
TGG ATC ACT TGG ATT GAC TGG TCA AAA AGC AAT CCT GAC ATA GGA ACT 
TGG ATC ACT TGG ATT GAC TGG TCA AAA AGC AAT CCT GAC ATA GGA ACT 
527 	 575 
GCC GTA GCT ATA GAA AAA GAT TTG GTT GTT TAT AGA ACT TTT AAT GTG 
GCC GTA GCT ATA GAA AAA GAT TTG GTT GTT TAT AGA ACT TTT AAT GTG 
GCC GTA GCT ATA GAA AAA GAT TTG GTT GTT TAT AGA NCT TTT AAT G 
576 	 620 
ATA GCT AAA GAA GGT GCG AGC AAA GAA ACA CAA GAT TTG GAT CC 
ATA GCT AAA GAAGGT GCG AGC AAA GAA ACA CAA GAT TTG GAT CC • M AA - G-- ----------------------------- 
Figure 5.3 cont. Sequence alignment of pGEM-TPEB3I with the expected PE133 clone 
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Figure 4.5 Map of pSAN3 showing important features 
4.2.4 Selection of an appropriate E. coil strain for the expression of 
His.PEB3 
pSAN3 was transformed into E. coli BL21 DE3 and induced as described in 
2.9. While all the transformants tested did express PEB3 as indicated by SDS-
PAGE, the level of expression was low and inconsistent (data not shown). This may 
have been due to either the expressed proteins insolubility (CV-CV' = 1.36 
(Wilkinson and Harrison, 1991)) or the difference in codon bias between E. coli 
(Henaut et aL, 1996) and C. jejuni (Gray and Konkel, 1999). 
Apparent solubility of a protein is affected by the folding characteristics, net 
charge and hydrophilicity of the protein. When expressed natively (i.e. at normal 
levels and the native organism) these factors ensure maximum solubility. When a 
protein is cloned and over expressed the non-optimal conditions can lead to incorrect 
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folding (see Figure 4.6) and inclusion body formation. By manipulation of factors 
controlling the expression (speed and level) it is possible to minimize inclusion body 
formation. To test whether solubility of the His.PEB3 was limiting expression, 
pSAN3 was transformed into another E. coli strain, TunerTM  DE3 pLysS (Novagen) 
and the expression profiles between the two strains compared. 




IPF =partially folded intermediate 
1PM = intermediate capably of forming mature protein 
IPM* = intermediate that generates inclusion body 
Figure 4.6 Mitraki and King model of inclusion body formation 
TunerTM DE3 pLysS cells are lacY] deletion mutants of E. coil BL2I. The 
lacY] gene codes for a lactose-specific transporter. Expression of lacY varies 
between cells from no expression to high levels of expression. This means that cells 
within a culture will be taking up IPTG at different rates and consequently the levels 
of expression between cells will vary within the culture. TunerTM DE3 pLysS cells 
cannot actively uptake IPTG and so all cells express at the same rate and the rate of 
expression is dependent on IPTG concentration. The rate at which a recombinant 
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protein is expressed has been shown to affect its apparent solubility. Additionally, 
the host strain contains the plasmid pLysS, which encodes the T7 lysozyme, and this 
prevents basal expression of the recombinant protein. Tuner DE3 pLysS cells 
allow fine control of the rate of expression and can enhance the apparent solubility of 
a recombinant protein. 
Two 500m1 cultures (1 BL21, 1 TunerTM)  were induced with 0.1 mM IPTG 
for 3 hours at 37°C with shaking. Total protein samples were run on 12.5 % 
(w/v) polyacrylamide cells and compared (data not shown). As before little or no 
expression was seen in the BL2I expression strain. Expression was seen in the 
TunerTM strain and so this was used in subsequent expression experiments. 
4.2.5 Selection of optimal expression conditions 
The conditions of protein expression were optimized to give the greatest 
possible yield. Two factors that have a large affect on the yield are the length of time 
between induction and harvest, and the concentration of IPTG used to induce. To 
find the optimum time between induction and harvest, one 500 ml culture was 
induced with 0.1 mM IPTG and time points were taken at 0.5, 1, 2, 3 hours and 
overnight. Total protein complement was then compared between each time point. 
No difference in the level of expression was seen after 1 h post-induction (data not 
shown). 
Cultures were induced with 0.1, 0.2, 0.4, 0.6, 0.8 and 1 mM IPTG at 37°C for 
3 hours with shaking. Aliquots (1 ml) of each culture were harvested and the total 
protein complement was compared (see Figure 4.7). Changing the IPTG 
concentration had no significant effect on the level of His.PEB3 expression. 
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Figure 4.7  12.5 % (w/v) polyacrylamide gel stained for total protein showing the affect 
of different IPTG concentrations on yield of His.PEB3 (indicated by arrow) after 
induction for 3 hours at 37 °C. 
4.2.6 Native vs. denaturing metal affinity purification of His.PEB3 
Two pathways are available for purification of a His-tagged protein; native 
and denaturing. The native pathway is the preferable pathway as it retains the 
conformation of the protein. The yield however, can be significantly less than using 
the denaturing method as the yield is affected by the efficiency of lysis and 
solubilization of the target protein. The yield of denaturing purification is often 
higher as lysis is more efficient and solubilization more complete, but the 
conformation of the protein is lost. 
Protein yield and purity was compared between four different purification 
methods: two native and two denaturing. Four 500m1 cultures of TunerTM  pSAN3 
were induced for 3 h at 37 °C with 1 mM IPTG. Each culture was then subjected to a 
different lysis method: (a) sonication (b) cell disruption (c) 8 M Urea (d) 6 M 
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Guanidine HCI. The first culture was exposed to 5 times 30 sec bursts of high-
frequency sound (sonication) with a 30 sec rest interval between each burst. The 
second culture was passed 3 times through a cell disrupter (Constant cell disruption 
systems, Daventry). These two native purifications were then treated identically. 
The third culture was treated as in 2.10. The fourth culture was treated with 
denaturing lysis buffer that had 6 M Guanidine HCI substituted for the 8 M Urea. 
Additionally, the equilibration of the nickel-agarose column used Guanidine HCI 
containing buffer but the column was washed and the protein eluted using a Urea 
based buffer. 
The purity of protein obtained was equivalent in each purification method 
(estimated at >95 % on a GelCode blue (Pierce) stained gel, see Figure 4.8). 
However, the yield of the native purification methods was less than half of the yield 
of the denaturing methods (see Table 4.2). The denaturing (urea) method was 
selected for purification of protein for use in raising antibodies. A final purification 
of 3 1 of induced TunefTm pSAN3, yielded 3.9 mg of protein. Protein from this lot 
was used in all further His.PEB3 experiments. 
Strategy 	 Protein Yield (pgml 1 ) 
Native (Sonication) 912 
Native (Cell Disrupter) 	 853 
Denaturing (Urea) 	 2238 
Denaturing (Guanidine HCL) 	 2087 










Figure 4.8 12.5% (w/v) polyacrylamide gel of a denaturing (urea) purification of 
His.PEB3 (indicated by arrows) from Tuner TM  pSAN3 cells. FT = Flow through, Elution 
I = eluent at pH 5.9, Elution 2 = eluent at pH 4.3 
4.3 Antibody production 
4.3.1 Production of monoclonal antibody against His.PEB3 
Two attempts at making monoclonal antibodies against His.PEB3 were 
performed. Purified His.PEB3 was dialysed against PBS, ready for mixing with 
Freund's complete or incomplete adjuvant. During dialysis the purified protein 
precipitated out of solution. The precipitated protein was vigourously resuspended 
and divided into aliquots containing 15 jig of protein. The aliquots were then sent 
to National Diagnostics (Bush, Scotland). The immunisation schedule is shown in 
2.12.1. 
Test bleeds were taken from two BALB/C mice before challenge and three 
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months post-challenge. Serum antibody levels were determined using ELISA and 
the end point titre calculated according to the equation: 
End point = 0 titre> Mean of 6 secondary antibody controls + 0.2 OD units 
Both mice had the same end point titre of 1:1024 (which suggest a reasonably poor 
response) and so it was decided to harvest the spleen from mouse I and keep mouse 
2 for use later. As well as harvesting the spleen, exsanguinate was collected and 
tested for anti-His.PEB3 antibodies (End point titre 1:2). Splenocytes were harvested 
on the same day as the splenectomy and frozen at -80 °C for 2 days. On the day of 
fusion I x 108  P3-X53-Ag8 (Ag8) myeloma cells were harvested and fused with the 
splenocytes. Tissue culture treated 96 well were seeded with 100 tl of fused cells 
per well (592 wells total). The fused cells were allowed to recover and then 
subjected to HAT selection to select hybridoma cells from splenocytes and 
myelomas. 
Wells were examined daily for the appearance of hybridoma colonies. When 
a hybridoma colony occupied approximately 1/3 to 1/2 of the well surface, the 
culture medium was tested for the presence of anti-His.PEB3 antibodies. A total of 
54 wells (9 %) had hybridoma colonies and were tested for antibody production. 
None of the hybridoma colonies tested positive for anti-His.PEB3 antibody 
production. 
Antibody amount and specificity is dependent on the processing of antigen by 
antigen presenting cells (APCs). Processing and presentation is known to be affected 
by: physical form of antigen, injection site, adjuvant used and the nature of the APC 
that encounters the antigen. How each factor increases or decreases the 
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immunogenicity of the antigen is specific to each antigen. As a result it is necessary 
to determine the affect of each factor empirically (Trombetta and Mellman, 2005). 
Table 4.3 lists factors that affect the immunogenicity of proteins and the effect seen 
with the majority of proteins. 
Parameter Increased immunogenicity Decreased 
immunogenicity 
Size Large Small (MW < 2 500) 
Dose Intermediate High or Low 
Route Subcutaneous> intraperitoneal > intravenous or intragastric 
Composition Complex Simple 
Form Particulate Soluble 
Denatured Native 
Similarity to self protein Multiple differences Few differences 
Adjuvants Slow release Rapid release 
Bacteria No bacteria 
Interaction with host MHC Effective Ineffective 
Table 4.3 Intrinsic protpeties and extrinsic factors that affect the immunogenicty of 
proteins. 
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To maximise the immunogenicity of the His.PEB3, it was decided to increase 
the dose per challenge from 15 jig to 100 jig. Two BA LB/C mice were challenged 
according to the schedule in 2.12.1. A pre-immune bleed and test bleed were taken 
and tested for anti-His.PEB3 antibodies. It was not possible to calculate and end 
point titre as before because only a small amount of sera (-. 30 jil) was supplied. 
However, both mice tested positive for antibody production with A492nm > 3 times the 
standard deviation of the negative control. As mouse I had responded marginally 
stronger, it was chosen for fusion and the splenocytes from mouse 2 harvested and 
frozen for later use. The exsanguinate from both mice was tested for the presence of 
anti-His.PEB3 antibodies and gave an end point titre of 1:2. 
Splenocytes from mouse 1 were fused with SP2/0'-Ag14 meyeloma cells 
using the same protocol as with Ag8 myelomas. The switch between myeloma cell 
lines was intended to increase the number of anti-His.PEB3 producing hybridomas, 
as SP2/0'-Agl4 is a non-producing cell line (see 1.7.1.1). After fusion, 96 well 
tissue culture treated plates were seeded with 100 jil of fused cells per well (576 
wells total). As soon as hybridoma colonies appeared, the culture media was tested 
for anti-His.PEB3 antibodies. No colonies tested positive for anti-His.PEB3 
production. 
In both experiments, an immune response against the His.PEB3 protein was 
observed, but no specific anti-His.PEB3 hybridomas produced. In the first 
experiment, the delay between the third challenge and the final challenge is the most 
likely cause. The spacing of challenges is designed to boost the immune response i.e. 
increase the number of B cells producing the desired antibody; as well as increasing 
the antibody affinity and diversity. During the time between the third challenge and 
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The pre-immune bleeds tested negative for all three rabbits (data not shown); the end 
point titre for all subsequent bleeds is shown in Figure 4.9. 







ii Bleed l 




Rabbit Ref Number 
Figure 4.9 Graph showing the levels of anti-His.PEB3 antibodies in three rabbits as 
determined by ELISA and calculation of end point titres. End point titres were 
calculated according to the equation: End point = 18t titre > mean of 6 secondary 
antibody controls + 0.2 OD units. Bleed I taken at 3 days, bleed 2 taken at 49 days, 
bleed 3 taken at 63 days and the exsanguinate at 77 days. 
4.4 Optimisation of IMS technique for maximum recovery of pure C. 
jejuni 
Polyclonal serum from rabbit 9711 was used in the following experiments, as 
it had the highest end point titre. It has been found that the maximum number of C. 
jejuni cells on a chicken carcass is generally 10 5 cells in total (Park et al., 1991). It is 
necessary to use saturating amounts of antibody in IMS; so that antibody binding and 
concentration is not a limiting factor. Excess antibody is not a problem as it will be 
removed by washing of captured cells. To determine the volume of sera that gave 
saturating amounts of antibody, varying volumes of sera (5 - 50 ILl) were mixed with 
I x 106  C. jejuni cells for 2 h. Excess and unbound antibody was then washed away 
before incubation with anti-rabbit IgG coated paramagnetic beads. After washing to 
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the final challenge it would be expected that the number of circulating B cells would 
decrease, antibody levels will fall and the number of memory cells would increase. 
After the final challenge it would be anticipated that memory cells would revert to B 
cells and cause an expansion in the B cell population. The quality of this expansion 
can be assessed by measuring the serum antibody levels. The low end point titre 
infers that either this expansion did not occur or was very small. Consequently, the 
efficiency of the fusion would be corresponding low. 
Similarly, in the second experiment a drop in antibody levels and therefore B 
cell numbers, occurred between the second challenge and exsanguinations. It would 
be expected that the third challenge would cause the B cell population to expand. 
The lack of expansion means that either the His.PEB3 was no longer immunogenic 
(e.g. completely degraded) or the inoculum was different from previous challenges 
(e.g. improper mixing, smaller dose). 
4.3.2 Production of high titre polyclonal serum with rabbits 
Although it is beneficial to use monoclonal antibodies in IMS, polyclonal sera 
can be used. The use of polyclonal sera would be expected to lower both sensitivity 
and specificity. Polyclonal sera were raised by challenging three New Zealand white 
rabbits with 1 tg of purified and dialysed His.PEB3. The challenges were carried 
out according to the schedule in 2.13.1 and by Harlan Seralabs (Hilcrest, UK). 
A pre-immune bleed, three test bleeds and exsanguinate were tested for the 
presence of anti-His.PEB3 antibodies by ELISA. The end point titres for each bleed 
were calculated according to the equation: 
End point = Pt titre > Mean of 6 secondary antibody controls + 0.2 OD units 
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remove any non-specifically bound or weakly bound material; captured cells were 
eluted from the beads and DAPI stained. Stained cells were then immobilised on 
black polycarbonate filters before counting under a microscope with UV excitation. 
No cells were recovered with any of the serum amounts tested. 
There are two possibilities as to why no cells were recovered using the 
polyclonal serum: 1. PEB3 is not surface exposed and 2. the polyclonal antibodies 
are not recognising native epitopes. The location of PEB3 within the cell is unknown 
but the evidence suggests that it is integral to the outer membrane (see Figure 4.10). 
PEB3 must at least be periplasmic as it is glycosylated and the attachment of the N-
linked glycan occurs in the periplasm (see 1.5.3.2). The glycosylation also suggests 
that it is surface exposed because glycosylation is thought to be involved in 
attachment to host cells and immune evasion; both of which would require the glycan 
to be surface exposed. Additionally, PEB3 was discovered by western blotting of an 
acid glycine extract, which preferentially extracts periplasmic and outer membrane 
associated proteins. Secondary structure prediction (see Figure 4.11) shows a 
number of alpha helices which is common to membrane embedded proteins. 
However, the size of the helices is too small for any to be transmembrane (minimum 
number of amino acids = 20). The most likely location of PEB3 is therefore, 
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Figure 4.10 Possible locations of the protein PEB3 based upon the current evidence. 
The most likely location is indicated by a circle with a solid line. 
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Figure 4.11 Predicted secondary structure for the protein PEB3. Blue lines indicate 
helices, red lines sheets and purple random coils. Arrows indicate the approximate 
location of the two potential glycosylation sites. Prediction performed using 
hierarchical neural network - 
(http://npsa-pbil. ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_nn.html)  
4.5 Conclusions 
The protein PE133 is conserved across C. jejuni strains and as such is a 
possible target for IMS. 
. The mice used for the production of monoclonal antibodies did not respond 
adequately. 
• The cloned protein was immunogenic producing a good response in rabbits. 
• The antibodies were not of sufficient quality or did not recognise native PEB3 
epitopes. 
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Discussion and Further Work 
5.1 C. jejuni typing schemes - one question, many answers! 
The knowledge that C. jejuni is the most prevalent cause of bacterial food-
poisoning has encouraged the research into typing schemes. A reliable typing 
scheme is critical for public health surveillance and for the comparison of data 
between multiple research laboratories. This need has given rise to a large number of 
typing schemes; some of which are extremely successful and others which have 
fallen into disuse. Of the typing systems currently in use, the Penner serotyping 
scheme, is perhaps the most important. This scheme was one of the first available 
and even with the advent of DNA-DNA based schemes, is still widely used. Other 
schemes in common use are: Lior serotyping, fla-RFLP, PFGE and MLST (see 1.6 
for descriptions of each scheme). 
It is possible to sustain multiple schemes because they fulfil differing 
requirements both scientific and practical (see Table 5.1). For example, fla-RFLP is 
a standardised technique that would most likely be used for following the course of 
an outbreak because it is easy to perform, relatively cheap and quick. Penner 
serotyping is useful for deciding treatment regimes as C. jejuni infection-associated 
diseases are often linked to particular serotypes (see 1.2). MLST is a good research 
tool as it can provide data about evolutionary relationships between strains; but is 
less likely to be used for public health as it is relatively expensive and slow to 
perform. 
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Typing Scheme Approximate 
time required 
Penner serotyping 3 days 
Lior serotyping 3 days 
fla-RFLP I to 3 days 
PFGE 5 days 
MLST 4 days 
Skill required 	Cost Level of 
discrimination 
Low 	 ++ 	+ 
Low 	 ++ 	+ 
Low 	 + 	++ 
Medium 	++ 	++ 
High 
	 +++ 	+++ 
Table 5.1 Typing schemes currently used with C. jejuni and C. coil and the factors 
affecting the usage of each scheme. 
The most important requirements that any typing system must fulfil are 
repeatability and portability. The portability of a scheme cannot be determined until 
the scheme has been used by multiple laboratories and the results compared. In the 
case of Campylobacter spp., an EU funded network (Campynet) was set up to 
investigate and devise standard protocols for the typing of C. jejuni and C. co/i. 
While this project succeeded for fla-RFLP and PFGE, a standardised protocol for 
AFLP was not produced. AFLP therefore is useful for intra- laboratory use but not 
for inter-laboratory comparisons. 
With the number of typing schemes available, the merit of developing of 
another is perhaps questionable. Although all the typing schemes fulfil the particular 
criteria for their niche, one significant problem remains. Each typing system stands 
alone and conversion of results from one scheme to another is difficult or impossible. 
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The aims of developing the CPS-RFLP typing scheme were: 
• To combine the simplicity/speed of RFLP schemes and create a DNA-DNA 
based system that is directly comparable to Penner serotyping. 
• To devise a scheme that might reveal data on the relationships between 
different serotypes. 
These aims could also be partially filled by the use of microarrays, which have been 
used as epidemiological tools (Wren et al., 2001). Microarrays are extremely 
powerful tools allowing the analysis of whole genomes and generate large amounts 
of data about each comparison. They therefore could easily reveal relationships at 
the DNA level between the different serotypes. At the same time this power makes 
them unsuitable for routine typing. As already stated some practical considerations 
that must be taken into account is the cost, technical skill required and the time taken 
to perform each test. Microarrays are a relatively new technology and so the cost 
associated with each test is very high and the technical skill required both to perform 
the test and analyse the data is high. CPS-RFLP would not be as discriminatory as 
using a microarray but would be considerably cheaper and easier to perform. 
Although amplifications of the CPS locus from strains other than C. jejuni 
NCTC 11168 failed, the in silico analysis showed that in theory the system would 
have fulfilled the first aim. A possible reason for the failure was the reliance on the 
ExpandTM 20 kb plus LT-PCR kit from Roche. There is considerable evidence to 
suggest that DNA polymerases are evolving to be more specific in the substrate they 
can process, as well as, becoming more accurate. The release of more LT-PCR 
systems means that the choice of enzymes available has expanded considerably since 
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the start of the project. Comparison of the enzymes within these kits to the C. jejuni 
DNA polymerase could determine whether any of the new kits would perform better 
than the ExpandTM kit. 
The new technique of whole genome amplification may also provide some 
possibilities. This technique uses the highly processive polymerase from the 
phage (p29 to amplify genomic DNA, using hexanucleotide primers, by rolling circle 
amplification (see Figure 5.1). The q29 DNA polymerase is unusual in that is 
highly processive (Blanco and Salas, 1984) and possesses extremely high fidelity 
(Esteban, 1993). Such whole genome amplifications produce 100 fold the starting 
amount of DNA with an average amplicon length of >10 kb. In such a system as the 
whole genome amplification the maximum possible amplicon length obtained is due 
in part to: 1. the length of time over which the amplification is performed (between 
1.5 and 5 h (GE Healthcare GenomiPhi amplification kits)) and 2. enzyme stability. 
The stability of the (p29 DNA polymerase would need to be improved before it could 
be used in traditional PCR type techniques; as it is mesophilic and inactivated by 
incubation at 60 °C in 10 min. 
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Figure 5.1 Schematic showing the process of whole genome amplification by ç29 DNA 
polymerase utilising hexanucleotide primers and strand displacement. 1. Replication 
initiates at multiple points on the chromosome by hexannucleotide primers and the 
DNA polymerase moves around the chromosome displacing strands of DNA 
synthesised by other polymerase molecules in front of it. 2. Hexanulceotide primers 
are then able to bind to the displaced strand. The polymerase is then able to initiate 
replication on the displaced strands, displacing any synthesised strands in front of it. 
3. The displacement-replication cycle continues until the reaction is stopped or 
dNTPs are exhausted. 
Another possible scheme to investigate the CPS locus as a target is multiplex 
PCR. This has been used successfully in Yersinia pseudotuberculosis to genetically 
'serotype' strains. In the case of Y. pseudotuberculosis the LPS loci of all of the 
serogroups were (see Figure 5.2) known and seven targets (eight genes) allowed each 
of the 15 serogroups to be distinguished (Bogdanovich et al., 2003). Although only a 
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few C. jejuni CPS loci are known the comparisons performed in 3.3.5 and the 
amplifications performed in 3.3.3 highlight some candidates for a multiplex PCR 
system. Such a scheme might include: 
. One kps gene as an internal control (all loci should contain the kps genes) 
. hddC and gmhA2. Found only in type 2 loci and was found in the majority of 
the reference strain set. 
• cj1430. Found only in type 2 loci and is less common than hddC or gmhA2. 
• fcl. The in silico analysis shows it to be present only in two of the sequenced 
loci. 
As more CPS loci sequences for C. jejuni become available, the construction of a 
multiplex PCR that would distinguish between serotypes would become easier. The 
sequences would also allow the multiplex PCR to be related to structural differences 
between the CPS of each serotype (as is the case in Y. pseudotuberculocis). Such a 
system would be easily comparable to the current Penner serotyping scheme and 
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Figure 5.2 Overview of the genetic organistaion of the 0-antigen gene clusters from Yersinia pseudotuberculosis serogroups 0:1- 
0:15. The top locus is the 0-antigen cluster from Y. pestis EV76. Light blue arrows indicate genes conserved between serogroups. 
Dark blue arrows indicate nonhomologus genes. The genes used for a genomic 'serotyping' scheme are listed above the 	The genes 
used for a genomic 'serotyping' scheme are listed above the V. pestis locus. (Adapted from Skurnik, 2003) 
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5.2 Selection of targets for IMS 
A number of IMS systems for the isolation of food borne pathogens, 
including C. jejuni, have been described (see Table 4.1). The success of each of 
these systems is dependent on both the target selected and quality (i.e. specificity and 
affinity) of the antibodies used. The results of the PEB3 based IMS detection system 
in Chapter 4 raise a number of questions: 
Was PEB3 a good choice of target for an IMS system? 
. What is the best method for selecting targets? 
• Is hybridoma-based antibody production the right choice for the production of 
antibodies? 
The selection of PEB3 as a target was influenced heavily by the successful 
application of PEB1 in an IMS system (Clark, 2000). The selection of PEB1 as a 
target was good because of its role in adherence to host cells factors, indicating that it 
is surface exposed. PEB4, which has been studied alongside PEB 1 would not make 
a suitable target for IMS as it is part of an ABC-transporter system and resides in the 
periplasm. Despite being detected simultaneously it appears that each of the PEB 
proteins are unrelated to each other. The detection of PEB4 alongside the other PEB 
proteins is most likely due to cell lysis during infection, allowing processing of 
periplasmic and cytoplasmic proteins by the immune system. 
The information on PEB3 suggests that it may have a similar function to 
PEB 1. PEB3 was the first protein to be identified as glycosylated by the N-linked 
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glycosylation system in C. jejuni. The N-linked glycan is known to be involved in 
adherence (Karlyshev et al., 2004) and cell competence (Larsen etal., 2004); both of 
which would require PE133 to be surface exposed. PEB3 therefore would seem to be 
ideal for a target of an IMS system. Other possible targets for IMS include the 
adherence factors that could be used as targets for IMS are CadF (Konkel et a!, 
1997), JlpA (Jin et al., 2001), MOMP (Schroder and Moser, 1997) and the 21 other 
glycosylated proteins that have been isolated from C. jejuni (Szymanski et al., 2003). 
Although all the available evidence suggests that PEB3 is a 'good' target, the 
failure to produce useful antibodies suggests that the methodology used to select it as 
a target is not ideal. When only minimal information is available for the surface 
composition of the bacteria, how should targets be selected? The answer to this 
question is dependent on the method by which the antibodies will eventually be 
produced. Traditionally monoclonal antibodies are produced by hybridoma 
production. This technique is however unsuitable when a target cannot be identified 
in advance. The technique is limited by its use of animals, the length of time it takes 
to be performed, the level of technical skill required and its cost. The newer 
technology of phage display and over-expression of antibodies within E. coli 
overcomes these limitations. 
Phage display (see 1.7.1.2) is a very powerful tool especially in the situation 
described above. Large numbers of possible targets can be screened very quickly 
and without any need for prior knowledge of the specific target. Phage display also 
provides a greater degree of control over the final antibody with fine tuning both of 
specificity and affinity being regulated. The only major problem with phage display 
is the creation of the initial antibody library. If the initial library is incorrectly 
146 
prepared then the some of the potential targets may be missed. Additionally, the 
creation of the initial library is relatively time consuming task and technically 
difficult task. The advantage being that once created the library can be used multiple 
times against multiple targets. 
With hindsight, hybridoma-based antibody production was not a suitable 
choice when such a small amount of information was available on PE133 because 
there is very little control over the final nature of antibodies. The use of phage 
display would have enabled screening of antibodies against the cloned protein and 
protein in its natural confirmation simultaneously; selecting for antibodies that will 
capture whole cells. Additionally the antibodies produced by hybridoma-based 
production are fixed in their properties. Once produced no further modification of 
affinity or specificity is possible. The properties of the antibodies are reliant on the 
quality of the host immune response; which for the BALB/C mice used in this 
experiment appeared to be of low quality. With the phage display method low 
quality antibodies can be artificially improved, with the use of site-directed 
mutagenesis or an E. co/i host strain with a high mutation rate, to produce antibodies 
with the desired properties. 
5.3 Further work 
Although neither the CPS-RFLP typing scheme or the IMS system fulfilled 
their initial aims, they both are worthy of further investigation. In theory the CPS-
RFLP scheme, would fill a gap in the current range of typing schemes in use. The 
unusually low %GC of the CPS locus will be problematic, as the majority of 
organisms currently being investigated are of higher %GC and consequently 
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protocols will be optimised as such. However, analysis of the information regarding 
ratios of enzymes in the LT-PCR kits and the organisms from which the enzymes are 
cloned should allow a selection of a kit suitable for use with C. jejuni. The 
comparison of the C. jejuni DNA polymerase to commercially available enzymes 
might help in the selection of enzymes better suited to low %GC templates. 
The identification of targets for IMS based upon the current information 
available is difficult and therefore identification of targets would be better 
accomplished with a phage display antibody library. If such an approach was 
followed the screening of the library should be performed: 
. On intact cells, thereby only producing antibodies against native epitopes. 
• As many C. jejuni strains as are available, allowing the selection of a 
conserved epitope. 
• Other intestinal organisms such as Arcobacter spp., E. co/i and 
Salmonella spp., to prevent cross reactivity. 
As already stated, phage display removes the need for prior knowledge of the target. 
It would therefore be necessary to identify the target post-screening by western 
blotting of cell surface extracts. The selection of targets in such a manner, would 
allow the production of an IMS system against the best target, without preconception. 
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Phosphate buffer composition 
Desired 0.2 	M sodium 	0.2 	M 	sodium Distilled 
pH phosphate, mono 	salt 	phosphate, di salt (ml) water (ml) 
(ml) 
5.7 93.5 6.5 100 
5.8 92.0 8.0 100 
5.9 90.0 10.0 100 
6.0 87.7  12.3 100 
6.1 85.0 15.0 	- 100 
6.2 81.5 18.5 100 
6.3 77.5 22.5 100 
6.4 73.5 26.5 100 
6.5 68.5 31.5 100 
6.6 62.5 37.5 100 
6.7 56.5 	---- 43.5  100 
6.8 51.0  49.0  100 
6.9 45.0 55.0 100 
7.0 39.0 61.0 100 
7.1 33.0 67.0 100 
7.2 28.0 72.0 100 
7.3 23.0 77.0 100 
7.4 19.0 81.0 100 
7.5 16.0 84.0  100 
7.6 13.0  87.0  100 
7.7 10.5 90.5 100 
7.8 8.5 91.5 100 
7.9 7.0 93.0 100 
8.0 5.3 94.7 100 
Appendix A Recipes for making 0.1 M sodium phosphate solution of a desired pH from 0.2 




144 	 218 
11168 kpsD (144) TAAAGAAAATAATCT 	 CCGCTCATCTTTTTA.TG 	H 
1221 kpsD (144) TAAAGAAAATAATCT_CTGCTCATCTTTTTAATG ATTTTAAAAA 
81116 kpsD 	(1) 	 *GCGCTCATCTTTTTAATG 	ATTTTAAAAA 
ST42 kpsD (1) --------------------------------------------------------- ----- ATTTTAAAA 
ST45 kpsD 	(1) 	 N 
	
Consensus (144) TACAAAAATTCATCAAATTTTAGTATTTGG GCTCATCTTTTTAATGGAAATTTTAAAAA 
219 	 293 
11168 kpsD (219) TTACAI 	 T 	.  
1221 kpsD (219) FTACAATCAAAGAGTTTATAACCCAGATTATAi, 	 IIGTGATCAAATCAGTCTTAAAATTTGGGGAGC 
81116 kpsD 	(61) TACAATCAAAGAGTTTATAACCCAGATTATAA T 	TGATCAAATCAGTCTTAJAATTTGGGGPtGC 
ST42 kpsD (14) PIAC!TCAAACTTTATAG.TTP.TJ\ 	:1 1 	ATCA7\ATCAGTCTTA.TTTGG(GAGC 
ST45 kpsD 	(53) 	H 	 H 	H. 1 7, .J 	J'CC . 	................;AGC 
Consensus (219) TTACAATCAAAGAGTTTATAACCCAGATTATAAGATCGCAGTTGGTGATCAAATCAGTCTTAAAATTTGGGGAGC 
294 	 368 
11168 kpsD 	(294) 	 H 	 -.i..,H .... 1 
1221 kpsD (294) ..TTTTC ;..ITTTTAGTGGTGGATTCTCAAGGAAATATTTTTATCCCTAAAGTAGGAGCTGTA'. 
81116 kpsD (136) .TTGAGTTTI :TTAGTGGTGGATTCTCAAGGAAATPTTTTTATCCCTAAAGTAGGAGCTGTAAATTT 
ST42 kpsD 	(89) 	 • 
ST45 kpsD 	(128) A 	NH!.'... 	.H 	 .. ...... . ......... 
Consensus (294) TGTTGAGTTTTCGCAAGTTTTAGTGGTGGATTCTCAAGGAAATATTTTTATCCCTAAAGTAGGAGCTGTAAATTT 
369 	 443 
11168 kpsD 	(369) 	L .. 	 . 1HiAit!.I(. ......1fA.' 	.11 AHr;A; CTA 
1221 kpsD (369) .TGTGAAAA . •. HTTGTAAGTGTTATA?..:.. $, GTTAATAAAATCTAThAMGCAAT 
81116 kpsD (211) ,:CTAGGTGTGAAAAI :HI ... .TTGTAAGTGTTATAIH . $ 	GTTAATAAAATCTATAAAAGCAATGTTTT 
ST42 	kpsD 	(164) 	 ,-., 	. 	. 	I 	................................................. 	.. 
ST45 kpsD 	(203) .. 	. 	... 	T 	 C . 	. 	 . 	. 
Consensus (369) ACTAGGTGTGAAAAATAGCGCCCTTGTAAGTGTTATAAAAGCACGTGTTAATAAAATCTATAAAAGCAATGTTTT 
Appendix A-I Alignments of the sequenced regions of kpsD from C. jejuni NCTC 11168, 81116, 3744 and 409266. Red on 
yellow residues indicate that the consesnsuu sequence was derived from a completely conserved residue. Blue on cyan 
residues indicate that the consensus sequence was derived from a block of conserved residues. Alignments were 
perfomed in VectorNTl vIO - AlignX module (Invitrogen) 
MIN 
11168 kpsD (444) 
1221 kpsD (444) 
81116 kpsD (286) 
ST42 kpsD (239) 














11168 kpsD (519) TCAAGGACTT,GTTCGGATT'' I I ATCTTGATAAAGCAGGGGGTATAAI 
1221 kpsD (519) CAAGGACTTAGTTCGGAT'I A .TCTTGATAAAGCAGGGGGTATAAA 
81116 kpsD (361) FCAAGGACTTAGTTCGGAT I I TCTTGATAAAGCAGGGGGTATAAAi' 
ST42 kpsD (314) I • 2.TCT-I--,-T,- 	 - 
ST45 kpsD (353) N A TC 
Consensus (519) TCAAGGACTTAGTTCGGATTCAGTGATCCAGTATCTTGATAAAGCAGGGGGTATAAATTTAGAATATGGAAGTTT 
Appendix A-I Alignments of the sequenced regions of kpsD from C. jejuni NCTC 11168, 81116, 3744 and 409266. Red on 
yellow residues indicate that the consesnsuu sequence was derived from a completely conserved residue. Blue on cyan 
residues indicate that the consensus sequence was derived from a block of conserved residues. Alignments were 
perfomed in VectorNTl vlO - AlignX module (Invitrogen) 
174 248 
GAGGTGTAAGTGTGATGAAAAATCTT A AATTTCThT ..RTTTTC #AAfMAA 
GAGGTGTAAGTGCGATGAAAAATCTT A AGC AT 
NNGAATNNNT NNNNNNAA N ---- NNG 	NGN N 	iT 
lAW G INU-____ _jTT 	l-G 
UAACIHG.l-- 	- 17C WI: 
GA CTTGAAA TTTCTATAGAGATTTTTTTCAA TAAAAAAATCGATGCTAT 
249 323 
TUAAUSTAAIGTCIC 	 • FAAI llT 	W 	I 
U:IUTAAIGTCITIC 	I 1:1 TM M • .RTATG 
NN 	N NCNINNAAANGGGNNG N 	G. N N CNTN 	GGN 	N ATATG 
U .. 	CCTUGGINT 	I U j NN 
TU::.Ic; CCNGGICr' I 	:Ir\TTAI1N :WI. 
TTTAATGTACCCT ATTG 	G ATTATACATGCTAAGGCTATTAAAGTGGC AAAGAATTAGGAATTGAAATATG 
324 398 
GATTI 	-A ,-; 	j 	 (f 	:i ii.1IGI.!  
ATT•TGAAGAAGGATATTTAAGGCCTTATTG• 	• ;AAAAAGATGGGGTGAATGCAAATT 
iATTG 	!'GAAGGATATTTAAGGCCTT 	' G ': AAAAPGATGGGGTGMTGCAAATT NN" 
Tii AGAAGGATATTTAAGGCCT , A11GP.TGGGGTGAATGC!\AAT: . •!fGG ...•: 	rGGG  
GATTTTTGAAGAAGGATATTTAAGGCCTTATTGTATTACTTTGGAAAAAGATGGGGTGAATGCAAATTCTTCTTT 
399 473 
i;A1'AJAJ\Ai rrTTAT 2l ITT C1tJT 	I Ii rTA: .AuAAcAT;::I 	W LiIATT • lTT 
N 	TAAAAATTTTTATCTTTCTCAAAATATTTTTACCAAAGAAAGCAT, . N 	NNN N 	\TT 
I 711777 (7,A j 	A rT 
I 2*1 I 
ACCGCGTGATAAAAATTTTTATCTTTCTCAAAATATTTTTACCAAAGAAAGCATAAAAGAAATTCCAGGTGGATT 
11168 KpsS (174) 
1221 KpsS (174) 
ST45 KpsS (1) 
ST49 KpsS (1) 
ST61 KpsS (1) 
Consensus (174) 
11168 KpsS (249) 
1221 KpsS (249) 
ST45 KpsS (44) 
ST49 KpsS (51) 
ST61 KpsS (50) 
Consensus (249) 
11168 KpsS (324) 
1221 KpsS (324) 
ST45 KpsS (119) 
ST49 KpsS (126) 
ST61 KpsS (125) 
Consensus (324) 
11168 KpsS (399) 
1221 KpsS (399) 
ST45 KpsS (194) 
ST49 KpsS (201) 
ST61 KpsS (200) 
Consensus (399) 
Appendix A-2 Alignments of the sequenced regions of kpsS from C. jejuni NCTC 11168, RM1221, 409266, 3060 and 
450964. Red on yellow residues indicate that the consesnsuu sequence was derived from a completely conserved 
residue. Blue on cyan residues indicate that the consensus sequence was derived from a block of conserved residues. 
Alignments were perfomed in VectorNTl vlO - AlignX module (lnvitrogen) 
11168 KpsS (474) 
1221 KpsS (474) 
ST45 KpsS (269) 
ST49 KpsS (276) 
ST61 KpsS (275) 
Consensus (474) 
11168 KpsS (548) 
1221 KpsS  
ST45 KpsS (343) 
ST49 KpsS (350) 
ST61 KpsS (350) 
Consensus  
11168 KpsS (621) 
1221 KpSS (621) 
ST45 KpsS (416) 
ST49 KpsS  
ST61 KPsS  
Consensus (624) 
11168 KpsS (696) 
1221 KpsS (696) 
ST45 KpsS (490) 
ST49 KpsS (497) 
ST61 KpsS (499) 
Consensus (699) 
474 548 
•\ I 	i'TIT 	• 	lU UU 	I I - 
• U GCTTTTG!. U U • • 	1 - 
Gi N 	GCTTTTGi 	GG: 	N GN 	NN NN 	•G ATT 	N NNNNNN 	- 	N 
I I U iUUR I I - s •• •a •u c 	.1 
TAAATTTATGGCTTTTGATGCTTTTTTGTATTGGTTGTTTGCTTTTATTTTGGCTCCATTTTTTAACAAC AAAC 
549 623 
• I 	l. I 	 . 	U 	II I I 	- I I 
NN N 	NN NN N: 	N NNNN: NGNNN NNNN 	NNN 	TT 	T T TI - N N NNN-NNN 
U I I IU1I I II I 	- IIT 
U I ILUI 	 . 	 • N A I i MTM. ,  
TTCATCATCGCACTTTATATCCTTTTGAATTTTTATTTTGGTTTAGATCATTGTATAGAAA GTATCTTT ATAA 
624 698 
'U. I 	Al 	U:UR,../t;AI, 	:;AAwj 	TTTT S 	TTTTA 	AGTTTI 
:5 I -A II AN 	-1 0 - I M:.:: 	J VACTTTTT a, TTTTA 	AGTTTA 
NN N :.NIN..NNI. NNNA NNN-N 	G GNNNNNNN IG 	NNNNN NNN 
I 	LCLU 	G1CTTT!LN  U• 
5'. 1 I;.C:j::.TGA 	G 	 TCNTTTTG NI 	NC 	GN 
GATTACAGAAAAAAAACTAA TGAAAAGATTTATAATTTAGAAAAAAAGTACTTTT GGCGATTTTACAAGTTNA 
699 773 
. 	 1A A IAAUGAL..iJ1IATIT 
I4A A AA 	AT : 	IIATI- T 
NGNGNGN--NGN INN 	NN--NNNNNNNN 	'I NNNI G GGGNNN-NN • I NINNNNN---NNNN 
M. 5N-TCTTNC 	...G ITU G FNNMN§G • . 	C CCI-G 
TICT. .NATCATTNkAJJ 	-5 N GNCTTN-1 C MCMCIC G 
TAGCGATACGCAAATTAAATP TCATT CAAAAAAAGC TNG GC CTTT TAGNGGAAACCNT CTT C TTT 
Appendix A-2 Alignments of the sequenced regions of kpsS from C. jejuni NCTC 11168, RM1221, 409266, 3060 and 
450964. Red on yellow residues indicate that the consesnsuu sequence was derived from a completely conserved 
residue. Blue on cyan residues indicate that the consensus sequence was derived from a block of conserved residues. 
Alignments were perfomed in VectorNll vlO - AlignX module (Invitrogen) 
774 848 
11168 KPSS (769) RA- 	-_____ IT 	ANTI- 	•.ARA--TAT IT-0 NAM T 
1221 KpsS (769) 5 5A5-5  I- 	ITS AUTU- ..5A5A--TAT IT-0 5A: T 
ST45 KpsS (557) GN ---NNGGN I--IGNNUIN INNNN__GNNNNI.NNNNNI ------GN GG-IN GGNNNNIN 
ST49 KpsS (570) GI RTNI-UNGIC 	TN 	CI-1G.SCINI--CNG IA-GI NTA 	A 
ST61 KpsS (572) 5 .UCUGBIGICNAI N C1A 5CACCNG INANI INTITIA 	A 
Consensus (774) GCAAACC TG CAAG AGCTAAANCTTNTC A GTTTTTAAAC CCN 	CCC 	GGA AGGGGCT TAAGAA 
Appendix A-2 Alignments of the sequenced regions of kpsS from C. jejuni NCTC 11168, RM1221, 409266, 3060 and 
450964. Red on yellow residues indicate that the consesnsuu sequence was derived from a completely conserved 
residue. Blue on cyan residues indicate that the consensus sequence was derived from a block of conserved residues. 
Alignments were perfomed in VectorNTl vlO - AlignX module (Invitrogen) 
